<!DOCTYPE html><html lang="en-US"><head><title>Advancements in Cholangiocarcinoma Treatment</title><meta property="og:title" content="Advancements in Cholangiocarcinoma Treatment"><meta name="author" content="Hsieh-Ting Lin"><meta property="article:author" content="Hsieh-Ting Lin"><meta charset="UTF-8"><meta name="viewport" content="width=device-width,height=device-height,initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>@media screen{body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{appearance:none;background-color:initial;border:0;color:inherit;cursor:pointer;font-size:inherit;opacity:.8;outline:none;padding:0;transition:opacity .2s linear;-webkit-tap-highlight-color:transparent}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:disabled{cursor:not-allowed;opacity:.15!important}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover{opacity:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:active{opacity:.6}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:not(:disabled){transition:none}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-prev{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNNjggOTAgMjggNTBsNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-next{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJtMzIgOTAgNDAtNDAtNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNNDAgNzBIMjBWNTBtMjAgMEwyMCA3MG00MC00MGgyMHYyMG0tMjAgMCAyMC0yMCIgY2xhc3M9ImEiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen]{background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNMjAgNTBoMjB2MjBtLTIwIDAgMjAtMjBtNDAgMEg2MFYzMG0yMCAwTDYwIDUwIiBjbGFzcz0iYSIvPjwvc3ZnPg==")}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNODcuOCA0Ny41Qzg5IDUwIDg3LjcgNTIgODUgNTJIMzVhOC43IDguNyAwIDAgMS03LjItNC41bC0xNS42LTMxQzExIDE0IDEyLjIgMTIgMTUgMTJoNTBhOC44IDguOCAwIDAgMSA3LjIgNC41ek02MCA1MnYzNm0tMTAgMGgyME00NSA0MmgyMCIvPjwvc3ZnPg==") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-bigger{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODBNNTIgOTBWMTAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-smaller{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}}@keyframes __bespoke_marp_transition_reduced_outgoing__{0%{opacity:1}to{opacity:0}}@keyframes __bespoke_marp_transition_reduced_incoming__{0%{mix-blend-mode:plus-lighter;opacity:0}to{mix-blend-mode:plus-lighter;opacity:1}}.bespoke-marp-note,.bespoke-marp-osc,.bespoke-progress-parent{display:none;transition:none}@media screen{::view-transition-group(*){animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-timing-function:ease}::view-transition-new(*),::view-transition-old(*){animation-delay:0s;animation-direction:var(--marp-bespoke-transition-animation-direction,normal);animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-fill-mode:both;animation-name:var(--marp-bespoke-transition-animation-name,var(--marp-bespoke-transition-animation-name-fallback,__bespoke_marp_transition_no_animation__));mix-blend-mode:normal}::view-transition-old(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_outgoing__;animation-timing-function:ease}::view-transition-new(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_incoming__;animation-timing-function:ease}::view-transition-new(root),::view-transition-old(root){animation-timing-function:linear}::view-transition-new(__bespoke_marp_transition_osc__),::view-transition-old(__bespoke_marp_transition_osc__){animation-duration:0s!important;animation-name:__bespoke_marp_transition_osc__!important}::view-transition-new(__bespoke_marp_transition_osc__){opacity:0!important}.bespoke-marp-transition-warming-up::view-transition-group(*),.bespoke-marp-transition-warming-up::view-transition-new(*),.bespoke-marp-transition-warming-up::view-transition-old(*){animation-play-state:paused!important}body,html{height:100%;margin:0}body{background:#000;overflow:hidden}svg.bespoke-marp-slide{content-visibility:hidden;opacity:0;pointer-events:none;z-index:-1}svg.bespoke-marp-slide:not(.bespoke-marp-active) *{view-transition-name:none!important}svg.bespoke-marp-slide.bespoke-marp-active{content-visibility:visible;opacity:1;pointer-events:auto;z-index:0}svg.bespoke-marp-slide.bespoke-marp-active.bespoke-marp-active-ready *{animation-name:__bespoke_marp__!important}@supports not (content-visibility:hidden){svg.bespoke-marp-slide[data-bespoke-marp-load=hideable]{display:none}svg.bespoke-marp-slide[data-bespoke-marp-load=hideable].bespoke-marp-active{display:block}}}@media screen and (prefers-reduced-motion:reduce){svg.bespoke-marp-slide *{view-transition-name:none!important}}@media screen{[data-bespoke-marp-fragment=inactive]{visibility:hidden}body[data-bespoke-view=""] .bespoke-marp-parent,body[data-bespoke-view=next] .bespoke-marp-parent{inset:0;position:absolute}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc{background:#000000a6;border-radius:7px;bottom:50px;color:#fff;contain:paint;display:block;font-family:Helvetica,Arial,sans-serif;font-size:16px;left:50%;line-height:0;opacity:1;padding:12px;position:absolute;touch-action:manipulation;transform:translateX(-50%);transition:opacity .2s linear;-webkit-user-select:none;user-select:none;white-space:nowrap;will-change:transform;z-index:1;view-transition-name:__bespoke_marp_transition_osc__}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>*,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>*{margin-left:6px}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>:first-child,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>:first-child{margin-left:0}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span{opacity:.8}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page]{display:inline-block;min-width:140px;text-align:center}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev]{height:32px;line-height:32px;width:32px}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive{cursor:none}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc{opacity:0;pointer-events:none}body[data-bespoke-view=""] svg.bespoke-marp-slide,body[data-bespoke-view=next] svg.bespoke-marp-slide{height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent{background:#222;display:flex;height:5px;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent+.bespoke-marp-parent{top:5px}body[data-bespoke-view=""] .bespoke-progress-parent .bespoke-progress-bar{background:#0288d1;flex:0 0 0;transition:flex-basis .2s cubic-bezier(0,1,1,1)}body[data-bespoke-view=next]{background:#0000}body[data-bespoke-view=presenter]{background:#161616}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container{display:grid;font-family:Helvetica,Arial,sans-serif;grid-template:"current dragbar next" minmax(140px,1fr) "current dragbar note" 2fr "info    dragbar note" 3em;grid-template-columns:minmax(3px,var(--bespoke-marp-presenter-split-ratio,66%)) 0 minmax(3px,1fr);height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent{grid-area:current;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide{height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide.bespoke-marp-active{filter:drop-shadow(0 3px 10px rgba(0,0,0,.5))}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container{background:#0288d1;cursor:col-resize;grid-area:dragbar;margin-left:-3px;opacity:0;position:relative;transition:opacity .4s linear .1s;width:6px;z-index:10}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container:hover{opacity:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container.active{opacity:1;transition-delay:0s}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container{background:#222;cursor:pointer;display:none;grid-area:next;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container iframe.bespoke-marp-presenter-next{background:#0000;border:0;display:block;filter:drop-shadow(0 3px 10px rgba(0,0,0,.5));height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container{background:#222;color:#eee;grid-area:note;position:relative;z-index:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper{display:block;inset:0;position:absolute}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons{background:#000000a6;border-radius:4px;bottom:0;display:flex;gap:4px;margin:12px;opacity:0;padding:6px;pointer-events:none;position:absolute;right:0;transition:opacity .2s linear}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons:focus-within,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper:focus-within+.bespoke-marp-presenter-note-buttons,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container:hover .bespoke-marp-presenter-note-buttons{opacity:1;pointer-events:auto}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note{box-sizing:border-box;font-size:calc(1.1em*var(--bespoke-marp-note-font-scale, 1));height:calc(100% - 40px);margin:20px;overflow:auto;padding-right:3px;white-space:pre-wrap;width:calc(100% - 40px);word-wrap:break-word;scrollbar-color:#eeeeee80 #0000;scrollbar-width:thin}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar{width:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-track{background:#0000}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-thumb{background:#eeeeee80;border-radius:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note:empty{pointer-events:none}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:first-child{margin-top:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:last-child{margin-bottom:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container{align-items:center;box-sizing:border-box;color:#eee;display:flex;flex-wrap:nowrap;grid-area:info;justify-content:center;overflow:hidden;padding:0 10px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{box-sizing:border-box;display:block;padding:0 10px;white-space:nowrap;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page{order:2;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page .bespoke-marp-presenter-info-page-text{display:inline-block;min-width:120px;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time{color:#999;order:1;text-align:left}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{color:#999;order:3;text-align:right}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer:hover{cursor:pointer}}@media print{.bespoke-marp-presenter-info-container,.bespoke-marp-presenter-next-container,.bespoke-marp-presenter-note-container{display:none}}</style><style>@charset "UTF-8";@import url("https://unpkg.com/markdown-it-admon/styles/admonition.css");@import url("https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css");@import url("https://fonts.googleapis.com/css2?family=Overpass+Mono:wght@400;500;600;700&display=swap");@import url("https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.2/font/bootstrap-icons.min.css");@import url("https://fonts.googleapis.com/css2?family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Lora:ital,wght@1,700&display=swap");@import url("https://unpkg.com/boxicons@2.1.4/css/boxicons.min.css");@import url("https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200");@import "components/_lists";div#\:\$p > svg > foreignObject > section{width:1280px;height:720px;box-sizing:border-box;overflow:hidden;position:relative;scroll-snap-align:center center;-webkit-text-size-adjust:100%;text-size-adjust:100%}div#\:\$p > svg > foreignObject > section::after{bottom:0;content:attr(data-marpit-pagination);padding:inherit;pointer-events:none;position:absolute;right:0}div#\:\$p > svg > foreignObject > section:not([data-marpit-pagination])::after{display:none}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1){font-size:2em;margin:0.67em 0}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls{will-change:transform}@page {size:1280px 720px;margin:0}@media print{html, body{background-color:#fff;margin:0;page-break-inside:avoid;break-inside:avoid-page}div#\:\$p > svg > foreignObject > section{page-break-before:always;break-before:page}div#\:\$p > svg > foreignObject > section, div#\:\$p > svg > foreignObject > section *{-webkit-print-color-adjust:exact!important;animation-delay:0s!important;animation-duration:0s!important;color-adjust:exact!important;transition:none!important}div#\:\$p > svg[data-marpit-svg]{display:block;height:100vh;width:100vw}}div#\:\$p > svg > foreignObject > :where(section):not([\20 root]){--JAMA-foreground: #333;--JAMA-current-line: #e5e5e5;--JAMA-background: #ffffff;--JAMA-comment: #6272a4;--JAMA-cyan: #192b2f;--JAMA-blue: #2d696a;--JAMA-green: #6c9a77;--JAMA-orange: #ffb703;--JAMA-pink: #9a2f6b;--JAMA-purple: #4f2d7d;--JAMA-red: #d71635;--JAMA-yellow: #8c9434;--box-shadow: 0 10px 14px rgba(0, 0, 0, 0.2);--box-padding: 20px;}div#\:\$p > svg > foreignObject > section{font-size:22px;font-weight:500;font-family:"Inter", sans-serif;line-height:1.15;padding:35px 35px;color:var(--JAMA-foreground);background-color:var(--JAMA-background);border-bottom:10px solid;border-image:linear-gradient(to bottom, #6c9a77, #2d696a);border-image-slice:1}div#\:\$p > svg > foreignObject > section{--marpit-root-font-size: 22px;}div#\:\$p > svg > foreignObject > section ul{line-height:1.5}div#\:\$p > svg > foreignObject > section ul strong, div#\:\$p > svg > foreignObject > section table strong, div#\:\$p > svg > foreignObject > section p strong{padding:0px 2px 0px 2px;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section .large-title{font-size:4em!important}div#\:\$p > svg > foreignObject > section section.large-title{--marpit-root-font-size: 4em !important;}div#\:\$p > svg > foreignObject > section br{break-before:column}div#\:\$p > svg > foreignObject > section.lg table, div#\:\$p > svg > foreignObject > section.lg > ul{font-size:1.5em!important;line-height:1.4}div#\:\$p > svg > foreignObject > section.xl table{font-size:1.8em!important}div#\:\$p > svg > foreignObject > section p{font-size:1em;margin:1em 0 1em 0}div#\:\$p > svg > foreignObject > section mark{font-size:120%;font-weight:700;color:var(--JAMA-blue);display:inline-block;background:transparent;background:#e0e0e0;border-radius:10px;padding:5px 10px;margin:2px 0;padding-bottom:3px;background-position:0 100%;background-repeat:no-repeat;background-size:100% 5px}div#\:\$p > svg > foreignObject > section ins::before{content:"[ ";font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section ins::after{content:" ]";font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section ins{font-size:1em;color:var(--JAMA-blue);text-decoration:none}div#\:\$p > svg > foreignObject > section.scroll > ul{overflow-x:hidden;overflow-y:auto}div#\:\$p > svg > foreignObject > section .outline li{font-size:1.2em;font-weight:700;color:#dddddd}div#\:\$p > svg > foreignObject > section .outline strong{font-size:1em}div#\:\$p > svg > foreignObject > section > *:first-child, div#\:\$p > svg > foreignObject > section > header:first-child + *{margin-top:0}div#\:\$p > svg > foreignObject > section code{border-radius:0.2em;border:1px solid var(--JAMA-blue);color:var(--JAMA-blue);display:inline-block;font-family:"Open Sans", sans-serif;font-weight:700;letter-spacing:0.5;margin:0.1em;padding:0.1em 0.3em 0.1em 0.3em;vertical-align:baseline;animation-name:fadeIn;animation-duration:0.3s;animation-fill-mode:both;animation-delay:0.2s}div#\:\$p > svg > foreignObject > section > p{transition:transform 0.2s ease}div#\:\$p > svg > foreignObject > section a{text-decoration:none;font-weight:700;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent;text-decoration:none}div#\:\$p > svg > foreignObject > section a::after{content:" 🔗"}div#\:\$p > svg > foreignObject > section > a:hover{background:#2d696a}div#\:\$p > svg > foreignObject > section em{font-family:"Lora", serif;font-weight:700;font-style:italic}div#\:\$p > svg > foreignObject > section.blue::after, div#\:\$p > svg > foreignObject > section footer, div#\:\$p > svg > foreignObject > section::after{box-sizing:border-box;line-height:30px;padding:10px 20px;position:absolute;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section::after{content:attr(data-marpit-pagination) " of " attr(data-marpit-pagination-total)}div#\:\$p > svg > foreignObject > section header{position:absolute;box-sizing:border-box;background-color:var(--JAMA-blue);font-weight:500;color:var(--JAMA-background)!important;border-bottom-left-radius:15px;border-top-left-radius:15px;font-size:18px;height:30px;padding:5px 20px;right:0;top:8;font-weight:400;text-align:right}div#\:\$p > svg > foreignObject > section header a{background:var(--JAMA-background);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section footer a:hover{background:var(--JAMA-blue);-webkit-background-clip:text;-webkit-text-fill-color:transparent;visibility:visible;opacity:1}div#\:\$p > svg > foreignObject > section footer a{text-decoration:none;opacity:0;transition:opacity 0.3s ease, visibility 0.3s ease}div#\:\$p > svg > foreignObject > section footer{left:0;right:0;bottom:0;font-size:14px}div#\:\$p > svg > foreignObject > section header strong{padding:0px 4px 0px 4px;font-weight:500;color:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section.noheader header{display:none}div#\:\$p > svg > foreignObject > section.medium{font-size:36px}div#\:\$p > svg > foreignObject > section.medium{--marpit-root-font-size: 36px;}div#\:\$p > svg > foreignObject > section.large{font-size:48px}div#\:\$p > svg > foreignObject > section.large{--marpit-root-font-size: 48px;}div#\:\$p > svg > foreignObject > section.small{font-size:18px}div#\:\$p > svg > foreignObject > section.small{--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section.happy{font-size:18px}div#\:\$p > svg > foreignObject > section.happy{--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section.two{column-count:2;column-gap:1em;padding:10px}div#\:\$p > svg > foreignObject > section.center :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section.center :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section.center :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section.center :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.center :is(h1, marp-h1){text-align:center;justify-content:center!important;max-width:100%}div#\:\$p > svg > foreignObject > section.three{column-count:3}div#\:\$p > svg > foreignObject > section.four{column-count:4}div#\:\$p > svg > foreignObject > section::after{right:0;bottom:0;font-size:14px}div#\:\$p > svg > foreignObject > section::after{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section.free{display:flex;width:100%;gap:1em}div#\:\$p > svg > foreignObject > section.free div{display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .cc{height:40px;left:40px;bottom:80px;position:absolute}div#\:\$p > svg > foreignObject > section .popup{position:fixed;top:20px;right:20px;background-color:#323232;color:#fff;padding:12px 20px;border-radius:4px;font-size:14px;box-shadow:0px 4px 6px rgba(0, 0, 0, 0.3);opacity:0;transform:translateY(-20px);transition:opacity 0.3s ease, transform 0.3s ease;z-index:1000}div#\:\$p > svg > foreignObject > section section.popup{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section .popup.show{opacity:1;transform:translateY(0)}div#\:\$p > svg > foreignObject > section .overlay{position:absolute;top:0;left:0;width:100%;height:100%;background-image:radial-gradient(#000 1px, transparent 1px);background-size:10px 10px;pointer-events:none}div#\:\$p > svg > foreignObject > section .diagram{padding:30px}div#\:\$p > svg > foreignObject > section .TD .level-1{display:flex;justify-content:center;gap:30px}div#\:\$p > svg > foreignObject > section .TD > .branch{display:flex;flex-direction:column;align-items:center}div#\:\$p > svg > foreignObject > section .TD > .node-group{display:flex;flex-direction:column;align-items:center;position:relative}div#\:\$p > svg > foreignObject > section .node{border:2px solid var(--JAMA-blue);padding:10px 20px;text-align:center;align-items:center;display:flex;justify-content:center;z-index:9}div#\:\$p > svg > foreignObject > section .TD .node{max-height:60px}div#\:\$p > svg > foreignObject > section .node > strong{white-space:nowrap}div#\:\$p > svg > foreignObject > section .branch > .node-group > .node{color:var(--JAMA-background);background:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section .TD .children{display:flex;gap:30px;margin-top:23px}div#\:\$p > svg > foreignObject > section .TD .node-group > .node{width:calc(100% - 44px);min-width:max-content;z-index:1}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node){position:relative}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node)::before{content:"";position:absolute;top:-25px;left:50%;width:1px;height:22px;background:#95a5a6;z-index:0}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node)::after{content:"";position:absolute;top:-11px;left:50.5%;transform:translateX(-50%);width:0;height:0;border-left:4px solid transparent;border-right:4px solid transparent;border-top:10px solid #95a5a6}div#\:\$p > svg > foreignObject > section .LR .level-1{display:flex;flex-direction:column;gap:50px}div#\:\$p > svg > foreignObject > section .LR .branch{display:flex}div#\:\$p > svg > foreignObject > section .LR .node{position:relative}div#\:\$p > svg > foreignObject > section .LR .node-group{display:flex;position:relative}div#\:\$p > svg > foreignObject > section .LR .node-group > .node{height:auto;align-self:stretch}div#\:\$p > svg > foreignObject > section .LR .children{display:flex;flex-direction:column;gap:30px;margin-left:25px;padding:0 0 0 0}div#\:\$p > svg > foreignObject > section .LR .node-group:has(.children){align-items:stretch}div#\:\$p > svg > foreignObject > section .LR .node-group .children .node::before{content:"";position:absolute;top:50%;left:-27px;width:25px;height:1px;background:#95a5a6}div#\:\$p > svg > foreignObject > section .LR .node-group .children .node::after{content:"";position:absolute;left:-11px;top:51%;transform:translateY(-50%);width:0;height:0;border-top:4px solid transparent;border-bottom:4px solid transparent;border-left:10px solid #95a5a6}div#\:\$p > svg > foreignObject > section.blue > :is(h1, marp-h1){font-size:0px;color:var(--JAMA-blue);position:absolute;top:20px;left:20px}div#\:\$p > svg > foreignObject > section.blue > :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.blue > :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section.blue > :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section.blue > :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section.blue > :is(h6, marp-h6), div#\:\$p > svg > foreignObject > section.blue > footer, div#\:\$p > svg > foreignObject > section.blue li, div#\:\$p > svg > foreignObject > section.blue li::marker, div#\:\$p > svg > foreignObject > section.blue::after{color:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section.blue a{color:var(--JAMA-background);background:none;-webkit-background-clip:border-box;-webkit-text-fill-color:initial;text-decoration:none}div#\:\$p > svg > foreignObject > section.blue a::after{content:none}div#\:\$p > svg > foreignObject > section.blue ol.agenda{font-size:0.8em;position:relative;list-style-type:upper-roman;padding-left:3em;top:40%;left:50%;line-height:1.5em;transform:translate(-50%, -50%)}div#\:\$p > svg > foreignObject > section.blue li.before{opacity:0.1}div#\:\$p > svg > foreignObject > section.blue li.current{font-weight:700;position:relative}div#\:\$p > svg > foreignObject > section.blue li.after{opacity:0.2}div#\:\$p > svg > foreignObject > section.blue li.after::marker{opacity:1!important}div#\:\$p > svg > foreignObject > section.blue{background:linear-gradient(50deg, var(--JAMA-blue) 20%, #6c9a77 100%);font-size:36px}div#\:\$p > svg > foreignObject > section.blue{--marpit-root-font-size: 36px;}div#\:\$p > svg > foreignObject > section.blue header{display:none}div#\:\$p > svg > foreignObject > section.blue footer.title_as_footer{left:60px}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1):first-of-type{padding-bottom:50px}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1){font-size:3em;font-weight:900;margin-bottom:20px;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section :is(h2, marp-h2){font-size:1.8em;font-weight:900;color:var(--JAMA-foreground);column-span:all}div#\:\$p > svg > foreignObject > section :is(h3, marp-h3){font-size:1.5em;font-weight:700;color:var(--JAMA-blue);column-span:all;padding-top:5px;padding-bottom:0.5em}div#\:\$p > svg > foreignObject > section :is(h4, marp-h4){font-weight:500;break-before:column;font-size:1.2em;color:var(--JAMA-blue);padding-top:25px}div#\:\$p > svg > foreignObject > section :is(h4, marp-h4).datetime{font-size:14px;position:absolute;text-align:center;bottom:18px;left:70px}div#\:\$p > svg > foreignObject > section :is(h5, marp-h5){font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section :is(h6, marp-h6){font-size:1em;font-style:italic;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section :is(h6, marp-h6){margin:0.2em 0 0 0;max-width:90%}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1) strong, div#\:\$p > svg > foreignObject > section :is(h2, marp-h2) strong, div#\:\$p > svg > foreignObject > section :is(h3, marp-h3) strong, div#\:\$p > svg > foreignObject > section :is(h4, marp-h4) strong, div#\:\$p > svg > foreignObject > section :is(h5, marp-h5) strong, div#\:\$p > svg > foreignObject > section :is(h6, marp-h6) strong{font-weight:inherit;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section .h2text, div#\:\$p > svg > foreignObject > section .bread{display:inline-block}div#\:\$p > svg > foreignObject > section .h2text{color:gray;padding-right:20px;font-size:0.8em}div#\:\$p > svg > foreignObject > section section.h2text{--marpit-root-font-size: 0.8em;}div#\:\$p > svg > foreignObject > section .firsth3afterh2{}@keyframes h2ToAnnotation{from{font-size:1.8em;font-weight:900;color:var(--JAMA-foreground);column-span:all;top:45px}to{color:gray;padding-right:20px;font-size:0.8em;position:absolute;top:30px}}div#\:\$p > svg > foreignObject > section.blue .menubar{display:none}div#\:\$p > svg > foreignObject > section .menubar{position:fixed;top:0;left:0;right:0;background:#fff;border-bottom:0.1px solid var(--JAMA-blue);z-index:1000;display:flex;justify-content:center}div#\:\$p > svg > foreignObject > section .menu{display:flex;gap:1em;margin:0;padding:0}div#\:\$p > svg > foreignObject > section .menu li{padding:0.2em;font-size:0.5em;color:#999!important;list-style:none}div#\:\$p > svg > foreignObject > section .menu li a{text-decoration:none;background:none;-webkit-background-clip:border-box;-webkit-text-fill-color:initial;text-decoration:none}div#\:\$p > svg > foreignObject > section .menu a::after{content:none}div#\:\$p > svg > foreignObject > section .menu li.done a{color:#999}div#\:\$p > svg > foreignObject > section .menu li.active a{font-weight:bold;padding:0px 10px;color:var(--JAMA-background)!important}div#\:\$p > svg > foreignObject > section .menu li.active{background-color:var(--JAMA-blue);font-weight:500;color:var(--JAMA-background)!important;list-style-position:inside;clip-path:polygon(0% 0%, 97% 0%, 100% 50%, 97% 100%, 0% 100%, 3% 50%)}div#\:\$p > svg > foreignObject > section .menu li.notyet a{color:#999}div#\:\$p > svg > foreignObject > section table{border-spacing:0;border-collapse:collapse;border-radius:2px;overflow:visible;margin:0;transition:transform 0.3s ease;margin:0 auto;z-index:1}div#\:\$p > svg > foreignObject > section table th, div#\:\$p > svg > foreignObject > section table td{font-size:0.8em;padding:0.4em 0.4em;border:1px solid var(--JAMA-background)}div#\:\$p > svg > foreignObject > section table th:last-child, div#\:\$p > svg > foreignObject > section table td:last-child{border-right:none}div#\:\$p > svg > foreignObject > section table thead th{background:var(--JAMA-blue);color:var(--JAMA-background);font-size:0.8em}div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(even) td, div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(even) th{background:var(--JAMA-current-line)}div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(odd) td, div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(odd) th{background:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section tr.emphasize, div#\:\$p > svg > foreignObject > section tr:hover{transform:scale(1.02);position:relative;z-index:10;outline:2px solid var(--JAMA-blue);outline-offset:-2px}div#\:\$p > svg > foreignObject > section tr.emphasize::after, div#\:\$p > svg > foreignObject > section tr:hover::after{content:"";position:absolute;bottom:-15px;left:5%;width:90%;height:10px;background:rgba(0, 0, 0, 0.2);filter:blur(9px);z-index:-1;pointer-events:none}div#\:\$p > svg > foreignObject > section tr{transition:all 0.3s ease;transform-origin:center}div#\:\$p > svg > foreignObject > section td:hover{color:#2d696a;transition:opacity 0.5s ease}div#\:\$p > svg > foreignObject > section .responsive-table tr:hover{transform:scale(1.02);background:#f9f9f9;box-shadow:0 4px 15px rgba(0, 0, 0, 0.1);position:relative;z-index:1}div#\:\$p > svg > foreignObject > section .responsive-table{width:100%;margin:20px 0;border-collapse:collapse;background:white;box-shadow:0 1px 3px rgba(0, 0, 0, 0.1)}div#\:\$p > svg > foreignObject > section .responsive-table th{background:#f5f5f5;padding:12px;text-align:left;font-weight:bold;color:#333;border-bottom:2px solid #ddd}div#\:\$p > svg > foreignObject > section .responsive-table td{padding:12px;border-bottom:1px solid #eee}div#\:\$p > svg > foreignObject > section .responsive-table tr:hover{background:#f9f9f9}@media screen and (max-width: 600px){div#\:\$p > svg > foreignObject > section .responsive-table{display:block;overflow-x:auto}}div#\:\$p > svg > foreignObject > section .url-card{border:1px solid #e5e7eb;border-radius:calc(var(--marpit-root-font-size, 1rem) * 0.375);overflow:hidden;background-color:white;box-shadow:0 1px 3px 0 rgb(0 0 0 / 0.1);margin:calc(var(--marpit-root-font-size, 1rem) * 0.75) 0;transition:box-shadow 0.2s ease-in-out;max-width:600px}div#\:\$p > svg > foreignObject > section .url-card:hover{box-shadow:0 4px 6px -1px rgb(0 0 0 / 0.1), 0 2px 4px -5px rgb(0 0 0 / 0.1)}div#\:\$p > svg > foreignObject > section .url-card-container{display:flex;min-height:90px}div#\:\$p > svg > foreignObject > section .url-card-image{width:45%;background-color:#f9fafb;position:relative;overflow:hidden}div#\:\$p > svg > foreignObject > section .url-card-image img{position:absolute;top:0;left:0;width:100%;height:100%;object-fit:cover}div#\:\$p > svg > foreignObject > section .url-card-content{width:55%;padding:calc(var(--marpit-root-font-size, 1rem) * 0.6);display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .url-card-title{font-size:calc(var(--marpit-root-font-size, 1rem) * 1);font-weight:600;margin-bottom:calc(var(--marpit-root-font-size, 1rem) * 0.375);color:#111827;display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-title{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 1);}div#\:\$p > svg > foreignObject > section .url-card-description{font-size:calc(var(--marpit-root-font-size, 1rem) * 0.875);color:#4b5563;margin-bottom:calc(var(--marpit-root-font-size, 1rem) * 0.375);flex-grow:1;display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-description{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 0.875);}div#\:\$p > svg > foreignObject > section .url-card-url{color:#6b7280;font-size:calc(var(--marpit-root-font-size, 1rem) * 0.75);margin-top:auto;display:-webkit-box;-webkit-line-clamp:1;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-url{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 0.75);}div#\:\$p > svg > foreignObject > section a.url-card{background:none;-webkit-background-clip:unset;-webkit-text-fill-color:initial;font-weight:normal;text-decoration:none;display:block}div#\:\$p > svg > foreignObject > section a.url-card::after{content:none}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre){display:block;min-height:1em;overflow:visible;margin:0;padding:0;position:relative;border-radius:0.5em}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code{box-sizing:border-box;line-height:1.5;background:#282a36;margin:0;min-width:100%;padding:1.2em;font-size:0.95em;color:#f8f8f2;overflow-x:auto;position:relative;display:block;font-family:"JetBrains Mono", "Fira Code", monospace;border-radius:0.5em;transition:all 0.3s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code svg[data-marp-fitting="svg"]{max-height:calc(480px - 1.2em)}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code[class*="language-"]::before{position:absolute;top:0.5em;right:0.5em;padding:0.2em 0.6em;font-size:0.7em;background:#44475a;color:#f8f8f2;border-radius:0.3em;font-family:"JetBrains Mono", monospace;z-index:10;opacity:0.9;transition:opacity 0.2s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre):hover code[class*="language-"]::before{opacity:1}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-javascript::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-js::before{content:"JavaScript"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-typescript::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-ts::before{content:"TypeScript"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-python::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-py::before{content:"Python"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-java::before{content:"Java"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-cpp::before{content:"C++"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-c::before{content:"C"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-css::before{content:"CSS"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-html::before{content:"HTML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-xml::before{content:"XML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-bash::before{content:"Bash"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-sh::before{content:"Shell"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-json::before{content:"JSON"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-yaml::before{content:"YAML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-markdown::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-md::before{content:"Markdown"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-sql::before{content:"SQL"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-rust::before{content:"Rust"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-go::before{content:"Go"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-ruby::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-rb::before{content:"Ruby"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-php::before{content:"PHP"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-r::before{content:"R"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-swift::before{content:"Swift"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-kotlin::before{content:"Kotlin"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-scala::before{content:"Scala"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-dart::before{content:"Dart"}div#\:\$p > svg > foreignObject > section .hljs-built_in, div#\:\$p > svg > foreignObject > section .hljs-selector-tag, div#\:\$p > svg > foreignObject > section .hljs-section, div#\:\$p > svg > foreignObject > section .hljs-link{color:#8be9fd;font-style:italic}div#\:\$p > svg > foreignObject > section .hljs-keyword{color:#ff79c6;font-weight:bold}div#\:\$p > svg > foreignObject > section .hljs-title, div#\:\$p > svg > foreignObject > section .hljs-attr, div#\:\$p > svg > foreignObject > section .hljs-meta-keyword{color:#50fa7b}div#\:\$p > svg > foreignObject > section .hljs-string, div#\:\$p > svg > foreignObject > section .hljs-meta, div#\:\$p > svg > foreignObject > section .hljs-name, div#\:\$p > svg > foreignObject > section .hljs-type, div#\:\$p > svg > foreignObject > section .hljs-symbol, div#\:\$p > svg > foreignObject > section .hljs-bullet, div#\:\$p > svg > foreignObject > section .hljs-addition, div#\:\$p > svg > foreignObject > section .hljs-variable, div#\:\$p > svg > foreignObject > section .hljs-template-tag, div#\:\$p > svg > foreignObject > section .hljs-template-variable{color:#f1fa8c}div#\:\$p > svg > foreignObject > section .hljs-comment, div#\:\$p > svg > foreignObject > section .hljs-quote, div#\:\$p > svg > foreignObject > section .hljs-deletion{color:#6272a4;font-style:italic}div#\:\$p > svg > foreignObject > section .hljs-literal, div#\:\$p > svg > foreignObject > section .hljs-number{color:#bd93f9}div#\:\$p > svg > foreignObject > section .hljs-keyword, div#\:\$p > svg > foreignObject > section .hljs-selector-tag, div#\:\$p > svg > foreignObject > section .hljs-literal, div#\:\$p > svg > foreignObject > section .hljs-title, div#\:\$p > svg > foreignObject > section .hljs-section, div#\:\$p > svg > foreignObject > section .hljs-doctag, div#\:\$p > svg > foreignObject > section .hljs-type, div#\:\$p > svg > foreignObject > section .hljs-name, div#\:\$p > svg > foreignObject > section .hljs-strong{font-weight:bold}div#\:\$p > svg > foreignObject > section .hljs-emphasis{font-style:italic}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol{all:unset;display:grid;grid-template-columns:auto 1fr;counter-reset:line-number 0;padding-right:1em}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li{display:contents;color:#f8f8f2;font-weight:400;line-height:1.5;font-family:"JetBrains Mono", monospace}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span){padding:0 0.5em;transition:all 0.2s ease;position:relative}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span):hover{font-weight:600;color:#ffb703}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span):hover::after{content:"";position:absolute;left:0;top:0;width:100%;height:100%;background:rgba(255, 255, 255, 0.1);border-radius:0.2em;pointer-events:none}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li :is(span, marp-span)[data-marp-line-number]::before{display:block;content:counter(line-number);counter-increment:line-number;text-align:right;color:#6272a4;font-weight:500;background:#2c2e3a;border-right:3px solid #44475a;margin-right:0.8em;padding:0 0.6em;transition:all 0.2s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li:hover :is(span, marp-span)[data-marp-line-number]::before{color:#8be9fd;border-right-color:#6272a4}@keyframes fadeIn{from{opacity:0;transform:translateY(1em)}to{opacity:1;transform:translateY(0)}}div#\:\$p > svg > foreignObject > section blockquote{opacity:0.7;font-size:10px!important;margin:5px 0 0 0;padding-top:5px;border-top:0.1px solid var(--JAMA-blue);margin-top:10px;color:var(--JAMA-foreground);position:absolute;bottom:0px;right:90px;left:25px}div#\:\$p > svg > foreignObject > section blockquote::before{content:"";display:block;font-weight:bold;position:absolute;color:var(--JAMA-green);top:0;left:0}div#\:\$p > svg > foreignObject > section blockquote > *:first-child{margin-top:0}div#\:\$p > svg > foreignObject > section blockquote > blockquote > blockquote{font-size:50%;font-weight:400;padding:0;margin:0;border:0;border-top:0.1em dashed #555;position:absolute;bottom:-10px;left:10px}div#\:\$p > svg > foreignObject > section blockquote::before, div#\:\$p > svg > foreignObject > section blockquote::after{color:var(--JAMA-comment)}div#\:\$p > svg > foreignObject > section .blur-shadow{position:relative}div#\:\$p > svg > foreignObject > section .blur-shadow::after{content:"";position:absolute;bottom:var(--blur-bottom, -4px);left:0;width:100%;height:var(--blur-height, 8px);background:var(--blur-color, rgba(0, 0, 0, 0.2));filter:blur(var(--blur-radius, 4px));z-index:-1;pointer-events:none}div#\:\$p > svg > foreignObject > section img.left{display:block;margin:0}div#\:\$p > svg > foreignObject > section img{display:inline-block;margin:0 auto}div#\:\$p > svg > foreignObject > section .outline li{font-size:1.2em;font-weight:700;color:#dddddd}div#\:\$p > svg > foreignObject > section .outline strong{font-size:1em}div#\:\$p > svg > foreignObject > section .free{display:flex;width:100%;gap:1em}div#\:\$p > svg > foreignObject > section .free div{display:flex;flex-direction:column;justify-content:center}div#\:\$p > svg > foreignObject > section .free > div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .free > div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .bigtable > div{justify-content:center;display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .bigtable > div > table{border-spacing:0;border-collapse:collapse;border-radius:9px;overflow:hidden;margin:1em 0 0 0;border:1px solid var(--JAMA-background)}div#\:\$p > svg > foreignObject > section .bigtable > div > table th, div#\:\$p > svg > foreignObject > section .bigtable > div > table td{text-align:center;font-size:1.8em;padding:0.4em 1.4em;border-left:50px solid var(--JAMA-background);border-right:50px solid var(--JAMA-background);background:#eeeeee}div#\:\$p > svg > foreignObject > section .bigtable > div > table thead th{text-align:center;background:var(--JAMA-blue);color:var(--JAMA-background);border-top:5px solid var(--JAMA-background);font-size:1.8em;color:white}div#\:\$p > svg > foreignObject > section .bigtable > div > table tbody > tr:nth-child(even) td, div#\:\$p > svg > foreignObject > section .bigtable > div > table tbody > tr:nth-child(even) th{background:var(--JAMA-current-line);font-size:1.8em}div#\:\$p > svg > foreignObject > section .even{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5);justify-content:space-between}div#\:\$p > svg > foreignObject > section .even > div img{width:calc(var(--marpit-root-font-size, 1rem) * 5.1)}div#\:\$p > svg > foreignObject > section .even div{display:flex;flex-direction:column;flex-grow:1;padding:15px;margin:10px 0}div#\:\$p > svg > foreignObject > section even :is(h2, marp-h2){display:flex;flex-direction:column;flex-grow:1;padding:15px;margin:10px 0}div#\:\$p > svg > foreignObject > section .boxlist{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5);justify-content:space-between}div#\:\$p > svg > foreignObject > section .boxlist div{display:flex;flex-direction:column;justify-content:center;flex-grow:1;background-color:#efefef;border-bottom:10px solid var(--JAMA-blue);padding:15px;margin:20px 20px}div#\:\$p > svg > foreignObject > section .boxlist ul{display:flex;flex-wrap:wrap;padding:0;margin:0}div#\:\$p > svg > foreignObject > section .boxlist ul li{display:inline-flex;margin-right:20px;list-style-type:none}div#\:\$p > svg > foreignObject > section .boxlist ul li::before{content:"● ";margin-right:8px}div#\:\$p > svg > foreignObject > section .top{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5)}div#\:\$p > svg > foreignObject > section .top div{justify-content:center}div#\:\$p > svg > foreignObject > section .container{display:flex}div#\:\$p > svg > foreignObject > section .tri{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .tri > div{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding:var(--box-padding);background-color:#efefef;border-bottom:10px solid var(--JAMA-blue);transition:transform 0.3s ease;margin:20px 0px}div#\:\$p > svg > foreignObject > section .tri > div > p > strong{font-size:1.5em;font-weight:900;color:var(--JAMA-blue);column-span:all}div#\:\$p > svg > foreignObject > section .tetra{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .tetra > div{flex:1;width:calc(25% - calc(var(--marpit-root-font-size, 1rem) * 0.5));border-bottom:10px solid var(--JAMA-blue);background-color:#efefef;padding:var(--box-padding);margin:20px 0px;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .third{display:flex;align-items:left;justify-content:space-between}div#\:\$p > svg > foreignObject > section .third > div{flex:1;padding-right:0.5em;box-sizing:border-box}div#\:\$p > svg > foreignObject > section .third img{max-width:340px!important;width:100%;height:auto}div#\:\$p > svg > foreignObject > section .twoone{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .twoone > div:first-child{flex:2;width:calc(66% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .twoone > div:last-child{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .onetwo{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .onetwo > div:first-child{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .onetwo > div:last-child{flex:2;width:calc(66% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .half{display:flex;justify-content:center;align-items:center;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .half > div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:1em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .half > div:hover, div#\:\$p > svg > foreignObject > section .free > div img:hover{transform:translateY(-10px);transform-origin:center;border-top-width:0px}div#\:\$p > svg > foreignObject > section .columns{padding-top:1em;padding-right:1em;display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .columns > div img:not(.emoji){display:block;margin:0 auto;max-width:100%;height:auto}div#\:\$p > svg > foreignObject > section .columns > div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5));transition:transform 0.3s ease;padding-right:0.5em}div#\:\$p > svg > foreignObject > section .columns div:not(:last-child){position:relative}div#\:\$p > svg > foreignObject > section .columns div:not(:last-child)::after{content:"";position:absolute;right:0;top:30px;bottom:30px;border-right:1px dashed #2d696a;width:0}div#\:\$p > svg > foreignObject > section .columns div:hover{transform:translateY(-5px);transform-origin:center;border-top-width:0px}div#\:\$p > svg > foreignObject > section hr{border:1px dashed var(--JAMA-blue);margin-top:10px;opacity:0.5;margin-bottom:10px}div#\:\$p > svg > foreignObject > section .dash{border:none;border-top:1px dashed #2d696a;height:0;margin:0.4em 0}div#\:\$p > svg > foreignObject > section.center{margin:0;max-width:100%!important;display:block;text-align:center;place-content:safe center center;padding:100px}div#\:\$p > svg > foreignObject > section.center{text-align:left}div#\:\$p > svg > foreignObject > section.center :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.center :is(h3, marp-h3){margin:1em!important;max-width:100%!important}div#\:\$p > svg > foreignObject > section a{color:var(--JAMA-cyan)}div#\:\$p > svg > foreignObject > section ul li:hover::marker{transform:scale(1.5);color:var(--JAMA-orange)}div#\:\$p > svg > foreignObject > section li{transition:opacity 0.3s ease;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section li::marker{color:#2d696a}div#\:\$p > svg > foreignObject > section li:hover{transition:transform 0.3s ease;text-decoration:underline;text-decoration-color:#6c9a77;text-decoration-style:solid;text-decoration-thickness:1px}div#\:\$p > svg > foreignObject > section .fa-solid{color:var(--JAMA-orange)}div#\:\$p > svg > foreignObject > section .scroll li:hover{transform:translateX(15px);transition:transform 0.2s ease;text-decoration:underline;text-decoration-color:#6c9a77;text-decoration-style:solid;text-decoration-thickness:5px}div#\:\$p > svg > foreignObject > section li[data-bespoke-marp-fragment="active"]{opacity:1;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section li[data-bespoke-marp-fragment="inactive"]{transition:transform 0.3s ease;visibility:visible;opacity:0.2}div#\:\$p > svg > foreignObject > section button{display:inline-block;outline:none;cursor:pointer;font-size:inherit;line-height:1;border-radius:200px;transition-property:background-color, border-color, color, box-shadow, filter;transition-duration:0.3s;border:1px solid transparent;letter-spacing:2px;min-width:160px;text-transform:uppercase;white-space:normal;font-weight:700;text-align:center;padding:2px 2px;margin-left:20px;color:#fff;background-color:#2d696a;height:48px}div#\:\$p > svg > foreignObject > section button :hover{transform:scale(1.04);background-color:#2d696a}div#\:\$p > svg > foreignObject > section .container{border:1px solid black;margin:10px}div#\:\$p > svg > foreignObject > section details{display:inline-block;position:relative}div#\:\$p > svg > foreignObject > section details > *:not(summary){position:absolute;z-index:50;margin-top:8px;padding:30px;width:356px;background:white;border-radius:8px;box-shadow:0 10px 15px -3px rgba(0, 0, 0, 0.1), 0 4px 6px -2px rgba(0, 0, 0, 0.05);border:1px solid #e5e7eb;font-size:18px;color:#4b5563;animation:fadeIn 0.2s ease-out}div#\:\$p > svg > foreignObject > section details > div#\:\$p > svg > foreignObject > section section:not(summary){--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section summary{cursor:pointer;padding:8px 16px;background:#f3f4f6;border-radius:20px;color:#4b5563;font-size:18px;font-weight:500;display:inline-flex;align-items:center;gap:8px;transition:background-color 0.2s ease;border:1px solid transparent}div#\:\$p > svg > foreignObject > section summary:hover{background:#e5e7eb}div#\:\$p > svg > foreignObject > section summary:focus{outline:none;border-color:var(--JAMA-blue);box-shadow:0 0 0 3px rgba(147, 197, 253, 0.3)}@keyframes fadeIn{from{opacity:0;transform:translateY(-4px)}to{opacity:1;transform:translateY(0)}}div#\:\$p > svg > foreignObject > section svg.markmap{width:200%}div#\:\$p > svg > foreignObject > section div[class^="admonition"]{column-span:all;margin:0.8em 10px 0.8em}div#\:\$p > svg > foreignObject > section div[class^="admonition"] > p > strong{font-weight:bold}div#\:\$p > svg > foreignObject > section p.admonition-title{padding:5px 0px 5px 40px;margin:15px 0px 0px 0px}div#\:\$p > svg > foreignObject > section p.admonition-title::before{padding-left:10px;padding-top:4px}div#\:\$p > svg > foreignObject > section .table-of-contents{font-size:14px;columns:2;list-style-type:disc}div#\:\$p > svg > foreignObject > section section.table-of-contents{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section .box{width:40%;margin:0 auto;background:rgba(255, 255, 255, 0.2);padding:35px;border:2px solid #fff;border-radius:20px/50px;background-clip:padding-box;text-align:center}div#\:\$p > svg > foreignObject > section .button{font-size:1em;padding:2px;border:2px solid #06d85f;text-decoration:none;cursor:pointer;transition:all 0.3s ease-out}div#\:\$p > svg > foreignObject > section section.button{--marpit-root-font-size: 1em;}div#\:\$p > svg > foreignObject > section .button:hover{background:#06d85f}div#\:\$p > svg > foreignObject > section .overlay{position:fixed;top:0;bottom:0;left:0;right:0;background:rgba(0, 0, 0, 0.7);transition:opacity 500ms;visibility:hidden;opacity:0}div#\:\$p > svg > foreignObject > section .overlay:target{visibility:visible;opacity:1}div#\:\$p > svg > foreignObject > section .popup{margin:70px auto;padding:20px;background:#fff;border-radius:5px;width:70%;position:relative;transition:all 5s ease-in-out}div#\:\$p > svg > foreignObject > section .popup :is(h2, marp-h2){margin-top:0;color:#333}div#\:\$p > svg > foreignObject > section .popup .close{position:absolute;top:20px;right:30px;transition:all 200ms;font-size:30px;font-weight:bold;text-decoration:none;color:#333}div#\:\$p > svg > foreignObject > section .popup div#\:\$p > svg > foreignObject > section section.close{--marpit-root-font-size: 30px;}div#\:\$p > svg > foreignObject > section .popup .close:hover{color:#06d85f}div#\:\$p > svg > foreignObject > section .popup .content{max-height:30%;overflow:auto}div#\:\$p > svg > foreignObject > section img[alt*="circle"]{border-radius:50%}div#\:\$p > svg > foreignObject > section ruby rt{color:deeppink}@media screen and (max-width: 1000px){div#\:\$p > svg > foreignObject > section .box{width:70%}div#\:\$p > svg > foreignObject > section .popup{width:70%}}div#\:\$p > svg > foreignObject > section .markmap > svg{width:100%;height:550px;font:300 16px/20px sans-serif}div#\:\$p > svg > foreignObject > section .material-symbols-outlined{font-size:140px;color:#2d696a;margin-bottom:2px;font-variation-settings:"FILL" 1, "wght" 500, "GRAD" 100, "opsz" 48}div#\:\$p > svg > foreignObject > section section.material-symbols-outlined{--marpit-root-font-size: 140px;}div#\:\$p > svg > foreignObject > section .bx{color:#2d696a}div#\:\$p > svg > foreignObject > section g{font-size:60px}div#\:\$p > svg > foreignObject > section .mdi-label{padding:0.2em 0.6em 0.3em;font-size:75%;font-weight:700;white-space:nowrap;vertical-align:baseline;border-radius:0.25em}div#\:\$p > svg > foreignObject > section section.mdi-label{--marpit-root-font-size: 75%;}div#\:\$p > svg > foreignObject > section .mdi-label-text-light{color:white}div#\:\$p > svg > foreignObject > section .mdi-label-text-dark{color:#332900}div#\:\$p > svg > foreignObject > section .tag{border:2px solid var(--JAMA-blue);border-radius:10px;padding:5px 10px;display:inline-block;color:var(--JAMA-blue);font-weight:bold;transition:transform 0.2s ease, box-shadow 0.2s ease}div#\:\$p > svg > foreignObject > section .tag:hover{transform:translateY(-5px);box-shadow:0 4px 8px rgba(0, 0, 0, 0.2)}div#\:\$p > svg > foreignObject > section ::selection{background-color:var(--JAMA-blue);color:white!important}div#\:\$p > svg > foreignObject > section .lab ul ul{display:inline-block;margin-left:auto;padding-left:0;list-style-type:none}div#\:\$p > svg > foreignObject > section .lab ul ul li{margin-right:10px}div#\:\$p > svg > foreignObject > section .row{display:flex;min-height:30vh;max-height:80vh;margin:50;flex-wrap:wrap}div#\:\$p > svg > foreignObject > section .row > ul:not(ul ul){flex:1;margin-left:150}div#\:\$p > svg > foreignObject > section .row > ul > li{padding:10px;flex:1;min-height:30vh}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul{padding:20px;background:var(--JAMA-blue);min-height:20vh}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul{border-radius:1px}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul, div#\:\$p > svg > foreignObject > section .row > ul > li:first-child li{font-size:24px;color:var(--JAMA-background);line-height:initial;weight:initial;list-style:none}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child{weight:900;line-height:2.5;text-align:center;list-style:none;font-size:1.5em!important;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section .c2, div#\:\$p > svg > foreignObject > section .c3, div#\:\$p > svg > foreignObject > section .c4{column-gap:20px;border-top:2px solid gray;padding-top:25px;margin-top:25px;min-height:60vh;column-fill:auto}div#\:\$p > svg > foreignObject > section .c2{column-count:2}div#\:\$p > svg > foreignObject > section .c3{column-count:3}div#\:\$p > svg > foreignObject > section .c4{column-count:4}div#\:\$p > svg > foreignObject > section.timeline > ul:first-of-type{display:flex;gap:10px;margin-top:255px;border-top:1px solid #999;margin:0}div#\:\$p > svg > foreignObject > section.timeline > ul:first-of-type code{border:2px solid var(--JAMA-blue)!important}div#\:\$p > svg > foreignObject > section.timeline > ul > li{padding-top:20px;border-left:1px dashed #999;padding-left:20px;list-style:none;break-before:column}div#\:\$p > svg > foreignObject > section.timeline :is(h2, marp-h2){padding-bottom:0.8em}div#\:\$p > svg > foreignObject > section.timeline mark{font-weight:500;font-size:1.2em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section.flexList :is(h2, marp-h2){padding-bottom:1em}div#\:\$p > svg > foreignObject > section.flexImg > ul, div#\:\$p > svg > foreignObject > section.flexList > ul{display:flex;flex-direction:row;gap:20px;padding:0px;line-height:2.5em;justify-content:space-evenly;position:relative}div#\:\$p > svg > foreignObject > section.flexList > ul > li{flex-grow:1;break-before:column}div#\:\$p > svg > foreignObject > section.flexList mark{font-weight:500;font-size:1.2em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section.flexImg > ul{list-style:none}div#\:\$p > svg > foreignObject > section.flexImg > ul > li img{max-width:100%;max-height:100%;object-fit:contain}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-volume-slider{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-mute-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-timeline{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-current-time-display{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-fullscreen-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-time-remaining-display{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-toggle-closed-captions-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-volume-slider{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-play-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-panel{background-image:none!important}div#\:\$p > svg > foreignObject > section .video-progress-container{width:100%;height:4px;background:rgba(255, 255, 255, 0.2);position:relative;overflow:hidden}div#\:\$p > svg > foreignObject > section .video-progress-bar{height:100%;background:#your-color-here;width:0;transition:width 0.2s ease}div#\:\$p > svg > foreignObject > section .markmap ul{padding-left:20px;position:relative;list-style-type:none}div#\:\$p > svg > foreignObject > section .markmap li{margin:0;padding:10px 5px;line-height:1.5;white-space:nowrap;position:relative}div#\:\$p > svg > foreignObject > section .markmap li::before, div#\:\$p > svg > foreignObject > section .markmap li::after{content:"";position:absolute;left:0}div#\:\$p > svg > foreignObject > section .markmap li::before{border-left:1px solid #000;top:0;bottom:50%;height:50%;width:20px}div#\:\$p > svg > foreignObject > section .markmap li::after{border-top:1px solid #000;top:50%;left:20px;width:calc(100% - 20px)}div#\:\$p > svg > foreignObject > section .markmap li > ul::before{content:"";position:absolute;top:0;left:0;border-left:1px solid #000;bottom:0;height:100%}div#\:\$p > svg > foreignObject > section .markmap ul ul{margin-left:20px;padding-left:0}div#\:\$p > svg > foreignObject > section .markmap li:first-child::before{height:50%}div#\:\$p > svg > foreignObject > section .markmap li:last-child::before{top:50%;height:50%}div#\:\$p > svg > foreignObject > section .markmap li:only-child::before{display:none}div#\:\$p > svg > foreignObject > section .markmap li:only-child::after{width:20px}div#\:\$p > svg > foreignObject > section .markmap ul ul::before{left:20px}div#\:\$p > svg > foreignObject > section .basic-label-container{fill:#f5f5f5;stroke:2px solid #333;padding:10px;border-radius:4px}div#\:\$p > svg > foreignObject > section.chat > ul{list-style:none;padding:0;margin:20px auto;max-width:600px;max-width:80%;margin-bottom:50px;display:flex;flex-direction:column;min-height:100px;justify-content:flex-end}div#\:\$p > svg > foreignObject > section.chat > ul::after{content:"Type a message...";display:block;padding:15px;padding-left:40px;background:white;border:1px solid #ddd;border-radius:35px;color:#999;margin-top:40px}div#\:\$p > svg > foreignObject > section.chat > ul li{margin:10px 0;padding:15px 20px;border-radius:25px;width:fit-content;max-width:80%}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(even){background-color:var(--JAMA-background);margin-right:auto;margin-left:0;border-bottom-left-radius:5px;position:relative}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(even)::before{content:"";position:absolute;left:-50px;top:50%;transform:translateY(-50%);width:40px;height:40px;border-radius:50%;background-image:url("lizard_realistic_small.jpg");background-size:cover;background-position:center;background-repeat:no-repeat}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(odd){background-color:#e0e0e0;margin-left:auto;margin-right:0;text-align:left;border-bottom-right-radius:5px}div#\:\$p > svg > foreignObject > section.chat > ul li:hover{transform:scale(1.1);text-decoration:none}div#\:\$p > svg > foreignObject > section.chat > ul li[data-bespoke-marp-fragment="inactive"]{display:none}div#\:\$p > svg > foreignObject > section svg[data-marp-fitting="svg"]{max-height:580px}div#\:\$p > svg > foreignObject > section img[alt*="uml"]{max-height:450px;width:auto}div#\:\$p > svg > foreignObject > section img{max-width:1200px!important;max-height:520px!important;width:auto;height:auto;object-fit:contain}div#\:\$p > svg > foreignObject > section img[alt*="inline"]{display:inline}div#\:\$p > svg > foreignObject > section img[alt*="badge"]{height:30px}div#\:\$p > svg > foreignObject > section img[alt*="svg"]{height:30px;font-family:"Inter", sans-serif}div#\:\$p > svg > foreignObject > section img[alt*="emojik"]{animation:move 2.5s infinite cubic-bezier(0.6, 0.05, 0.4, 0.95)}div#\:\$p > svg > foreignObject > section img[alt*="RLQ"]{position:absolute;right:80px;bottom:80px;z-index:0}div#\:\$p > svg > foreignObject > section .webcam-container{position:absolute;right:80px;bottom:80px;display:flex;margin:10px auto;width:250px;height:250px;border:8px solid var(--JAMA-blue);border-radius:50%}div#\:\$p > svg > foreignObject > section .webcam-video{width:100%;height:100%;object-fit:cover;z-index:0;border-radius:inherit}div#\:\$p > svg > foreignObject > section img[alt*="RUQ"]{position:absolute;right:80px;top:80px}div#\:\$p > svg > foreignObject > section img{animation-name:fadeIn;animation-duration:0.2s;animation-fill-mode:both;animation-delay:0.3s}div#\:\$p > svg > foreignObject > section a.wikilink{display:inline;color:#0366d6;text-decoration:none;border-bottom:1px dashed #0366d6;padding-bottom:1px;transition:all 0.2s ease;opacity:1!important;visibility:visible!important}div#\:\$p > svg > foreignObject > section a.wikilink:hover{color:#0056b3;border-bottom:1px solid #0056b3;text-decoration:none}div#\:\$p > svg > foreignObject > section a.wikilink[href="#table-of-contents"]{color:inherit;border-bottom:1px dashed currentColor}div#\:\$p > svg > foreignObject > section li a.wikilink, div#\:\$p > svg > foreignObject > section td a.wikilink{margin:0 2px}div#\:\$p > svg > foreignObject > section code a.wikilink{border-bottom:none;padding-bottom:0}div#\:\$p > svg > foreignObject > section sup, div#\:\$p > svg > foreignObject > section sub{font-size:0.8em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section kbd{background-color:#eee;border:0;border-radius:0.125em;box-shadow:+0.2em +0.125em 0.125em rgba(0, 0, 0, 0.25), 0 0 0 0.04em rgba(0, 0, 0, 0.3), 0.02em 0.02em 0.02em rgba(0, 0, 0, 0.4) inset, +0.05em +0.05em 0.02em rgba(255, 255, 255, 0.8) inset;color:var(--JAMA-foreground);display:inline-block;padding:0.2em 0.4em;margin:0 0.35em;font-family:"JetBrains Mono", monospace;font-size:1em;cursor:pointer;user-select:none;transition:all 0.2s ease}div#\:\$p > svg > foreignObject > section kbd:hover{background-color:#eee;border-radius:0.125em;background-color:#f3f3f3;box-shadow:0 4px 8px rgba(0, 0, 0, 0.2)}div#\:\$p > svg > foreignObject > section kbd:active{background-color:#e6e6e6;box-shadow:0.1em 0.1em 0.1em rgba(0, 0, 0, 0.2), 0 0 0 0.05em rgba(0, 0, 0, 0.4), -0.025em -0.05em 0.025em rgba(255, 255, 255, 0.8) inset;transform:translateY(5px)}div#\:\$p > svg > foreignObject > section .markdown-alert{display:flex;gap:calc(var(--marpit-root-font-size, 1rem) * 2);padding:0.5em;border-left:calc(var(--marpit-root-font-size, 1rem) * 0.2) solid;padding-bottom:0px;padding-top:0px;border-color:var(--border-color);background-color:#f1f1f1}div#\:\$p > svg > foreignObject > section .markdown-alert > p{line-height:1em}div#\:\$p > svg > foreignObject > section .markdown-alert > :is(span, marp-span){display:flex;flex-direction:row;align-items:center;color:var(--border-color)}div#\:\$p > svg > foreignObject > section .markdown-alert .markdown-alert-icon{margin-right:0.5em;fill:var(--border-color)}div#\:\$p > svg > foreignObject > section .markdown-alert.note{--border-color: #539bf5;}div#\:\$p > svg > foreignObject > section .markdown-alert.warning{--border-color: #c69026;}div#\:\$p > svg > foreignObject > section .markdown-alert.important{--border-color: #986ee2;}div#\:\$p > svg > foreignObject > section .markdown-alert.caution{--border-color: #e5534b;}div#\:\$p > svg > foreignObject > section .markdown-alert.tip{--border-color: #57ab5a;}div#\:\$p > svg > foreignObject > section .task-list-item-checkbox{transform:scale(1.5)}@keyframes weightChange{0%{font-variation-settings:"wght" 500;letter-spacing:1px}100%{font-variation-settings:"wght" 800;letter-spacing:10px}}div#\:\$p > svg > foreignObject > section .animated-text{font-variation-settings:"wght" 500;animation:weightChange 0.5s ease-in-out infinite alternate}@keyframes underline-animation{0%{color:var(--JAMA-foreground);background-size:0% 44px;background-position:0 100%}100%{color:var(--JAMA-background);background-size:110% 44px;background-position:0% 100%}}@keyframes pulse{0%{font-variation-settings:"wght" 200}50%{font-variation-settings:"wght" 500}100%{font-variation-settings:"wght" 200}}@keyframes head-fade-in{from{opacity:0;transform:translateY(-40px)}to{opacity:1;transform:translateY(0)}}@keyframes move{0%{transform:translateX(0)}50%{transform:translateX(-20px)}100%{transform:translateX(0)}}@keyframes slideInRight{from{transform:translateX(100%)}to{transform:translateX(0)}}@keyframes fadeIn{from{opacity:0}to{opacity:1}}@keyframes fade{0%{opacity:0}50%{opacity:1}100%{opacity:0}}@keyframes typewriter{from{width:0}to{width:100%}}@keyframes blinkTextCursor{from{border-right-color:rgba(0, 0, 0, 0.75)}to{border-right-color:transparent}}@keyframes bounceSize{0%, 100%{transform:scale(1);transform-origin:left center}50%{transform:scale(1.05)}}@keyframes underline-animation{0%{color:var(--JAMA-foreground);background-size:0% 44px;background-position:0 100%}100%{color:var(--JAMA-background);background-size:110% 44px;background-position:0% 100%}}div#\:\$p > svg > foreignObject > section ::view-transition-group(*){animation-duration:300ms}div#\:\$p > svg > foreignObject > section ::view-transition-old(*), div#\:\$p > svg > foreignObject > section ::view-transition-new(*){mix-blend-mode:normal}div#\:\$p > svg > foreignObject > section ::view-transition * svg, div#\:\$p > svg > foreignObject > section ::view-transition * foreignObject{transition:none;animation:none}div#\:\$p > svg > foreignObject > :where(section){container-type:size}div#\:\$p > svg > foreignObject > section img[data-marp-twemoji]{background:transparent;height:1em;margin:0 .05em 0 .1em;vertical-align:-.1em;width:1em}/*!
 *
 * @auto-scaling true
 * @size 4:3 960px 720px
 * @size 16:9 1280px 720px
 * @size 21:9 1680px 720px
 * @size 32:9 2560px 720px
 */div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]{columns:initial!important;display:block!important;padding:0!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]::before, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]::after, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"]::before, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"]::after{display:none!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container]{all:initial;display:flex;flex-direction:row;height:100%;overflow:hidden;width:100%}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container][data-marpit-advanced-background-direction="vertical"]{flex-direction:column}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"][data-marpit-advanced-background-split] > div[data-marpit-advanced-background-container]{width:var(--marpit-advanced-background-split, 50%)}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"][data-marpit-advanced-background-split="right"] > div[data-marpit-advanced-background-container]{margin-left:calc(100% - var(--marpit-advanced-background-split, 50%))}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container] > figure{all:initial;background-position:center;background-repeat:no-repeat;background-size:cover;flex:auto;margin:0}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container] > figure > figcaption{position:absolute;border:0;clip:rect(0, 0, 0, 0);height:1px;margin:-1px;overflow:hidden;padding:0;white-space:nowrap;width:1px}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"], div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="pseudo"]{background:transparent!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="pseudo"], div#\:\$p > svg[data-marpit-svg] > foreignObject[data-marpit-advanced-background="pseudo"]{pointer-events:none!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background-split]{width:100%;height:100%}
</style></head><body><div class="bespoke-progress-parent"><div class="bespoke-progress-bar"></div></div><div class="bespoke-marp-osc"><button data-bespoke-marp-osc="prev" tabindex="-1" title="Previous slide">Previous slide</button><span data-bespoke-marp-osc="page"></span><button data-bespoke-marp-osc="next" tabindex="-1" title="Next slide">Next slide</button><button data-bespoke-marp-osc="fullscreen" tabindex="-1" title="Toggle fullscreen (f)">Toggle fullscreen</button><button data-bespoke-marp-osc="presenter" tabindex="-1" title="Open presenter view (p)">Open presenter view</button></div><html><head></head><body><div id=":$p"><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="1" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="1" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="firstH1Page"><img src="https://i.imgur.com/Shai2kG.png" alt="Ⓒ" class="cc">
<h1 id="advancements-in-cholangiocarcinoma-treatment" tabindex="-1">Advancements in Cholangiocarcinoma Treatment</h1>
<h4 id="speaker-fellow-2-%E6%9E%97%E5%8D%94%E9%9C%86-brmoderator-%E9%99%B3%E6%96%B0%E7%82%AB%E9%86%AB%E5%B8%AB" tabindex="-1"><code>Speaker</code> Fellow 2 林協霆  <br><code>Moderator</code> 陳新炫醫師</h4>
<p><strong>Hsieh-Ting Lin, <a href="mailto:htlin222@kfsyscc.org">htlin222@kfsyscc.org</a></strong></p>
<p><img src="https://i.imgur.com/TLuxHNS.png" alt="" style="height:50px;"></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="2" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="2" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 id="case" tabindex="-1">Case</h1><ol class="agenda"><li class="current"><a href="#case">Case</a></li><li class="after"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="after"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="3" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="3" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="72-year-old-man---06103741" tabindex="-1">72-year-old man - <code>06103741</code></h2>
<p>he was diagnosed as DM since 2023/9 s/p oral medication control. fast sugar around 100, HbA1c= 6.5%</p>
<ul>
<li>no history of GU infection, hematuria or stone</li>
<li>BWL 20kg: used to be around 73kg as normal body weight, BW around 50s since DM diagnosis. no recovery since then
<ul>
<li>=&gt; <mark>53.7 kg</mark> today （2023/9 since diagnosed with DM ）</li>
</ul>
</li>
</ul>
<hr>
<p>Home medication:<br>
metformin 500mg BID<br>
dabigatran 110mg BID<br>
propranolol 10mg BIDprn</p>
<hr>
<p>smoking -<br>
alcohol, beer<br>
betel -<br>
鐵路局技術員退休 <i class="fa-sharp fa-solid fa-bars"></i>（有空氣汙染的暴露 20-30 年）</p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/794HgYN.png&quot;);background-size:auto 600px;"></figure></div></section></foreignObject><foreignObject width="35%" height="720"><section id="4" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">72-year-old man - 06103741</div><h3 id="ct-whole-abdomen-plaincontrast" tabindex="-1">CT Whole Abdomen plain&amp;contrast</h3>
<p>Impression and Suggestions</p>
<ol>
<li>Hepatic tumors. Nature to be determined.</li>
<li>Multiple metastatic lymph nodes.</li>
<li>Pulmonary nodules, probably metastasis.</li>
</ol>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Ph6KE9h.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="5" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text">72-year-old man - 06103741</div><h3 id="mri" tabindex="-1">MRI</h3>
<p>Heterogenous poor enhancing large mass lesion occupying S4 to S8 of the liver with hepatic hilum<br>
compression, left IHD dilatation and multiple metastatic lymphadenopathy at hepatic hilum to bilateral<br>
para-aortic retroperitoneum, portal caval region with necrosis and ill-defined margin, in favor of<br>
extracapsular invasion of lymphadenopathy.</p>
<p><img src="https://i.imgur.com/BvWzvsK.png" alt="" style="height:250px;"></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="6" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="6" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h4 id="pathologic-diagnosis" tabindex="-1">Pathologic diagnosis</h4>
<p>Liver, core biopsy: ADENOCARCINOMA. 2024/10/17<br>
HER2: negative, no staining is observed, score: 0 (no overexpression)</p>
<h4 id="treatment-course" tabindex="-1">Treatment course</h4>
<ul>
<li>GC (Gemcitabine+Cisplatin) x8a 2024/04/19 ~ 2024/09/20</li>
<li>Pembrolizumab + Gemcitabine x4 2024/10/29 ~ 2024/12/31</li>
</ul>
<div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p><img src="https://i.imgur.com/u8MNdO4.png" alt="" style="height:22px;">:肝內膽管癌：先前曾接受過至少一次全身性治療失敗，又有疾病惡化，無法手術切除或晚期或復發之膽道癌（含肝內膽管）病患。</p>
</div><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="7" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="7" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Clinical Presentation, Diagnosis" id="clinical-presentation-diagnosis" tabindex="-1">Clinical Presentation, Diagnosis</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="current"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="after"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/EUREPzC.png&quot;);background-size:auto 500px;"></figure></div></section></foreignObject><foreignObject width="45%" height="720"><section id="8" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="characteristics-and-anatomical-features-of-biliary-tract-cancers" tabindex="-1">Characteristics and Anatomical Features of Biliary Tract Cancers</h2>
<p><img src="https://i.imgur.com/BqymkEr.jpeg" alt="" style="height:350px;"></p>
<blockquote><p>Goyal L, Chen CT, Pierce TT, Deshpande V. Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. New England Journal of Medicine. 2021;384(11):1054-1064. doi:10.1056/nejmcpc2027092<br>
Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer discovery. 2017;7(9):943-962. doi:10.1158/2159-8290.CD-17-0245</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="9" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="9" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="presentation-and-workup" tabindex="-1">Presentation and Workup</h2>
<p><img src="https://i.imgur.com/0gWhnL4.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:40%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/HYT0cbA.png&quot;);background-size:auto 350px;"></figure></div></section></foreignObject><foreignObject width="60%" height="720"><section id="10" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:40%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="btc-staging-per-ajcc-8th" tabindex="-1">BTC Staging, per AJCC 8th</h2>
<br>
<p><img src="https://i.imgur.com/59jlOp7.png" alt="" style="height:350px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers<br>
AJCC Version 9 Cancer Staging System. ACS. Accessed January 11, 2025. <a href="https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/">https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/</a></p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="11" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="11" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="molecular-testing-in-advanced-biliary-tract-cancer" tabindex="-1">Molecular Testing in Advanced Biliary Tract Cancer</h2>
<p><img src="https://i.imgur.com/0phUebz.png" alt="" style="height:650px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="12" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="12" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">Molecular Testing in Advanced Biliary Tract Cancer</div><h3 id="common-genetic-alterations-in-intrahepatic-and-extrahepatic-cholangiocarcinoma-cca" tabindex="-1">Common genetic alterations in intrahepatic and extrahepatic cholangiocarcinoma (CCA)</h3>
<p><img src="https://i.imgur.com/yRWn0XY.jpeg" alt="" style="height:450px;"></p>
<blockquote><p>Normanno N, Martinelli E, Melisi D, et al. Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open. 2022;7(3). doi:10.1016/j.esmoop.2022.100505</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="13" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="13" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text">Molecular Testing in Advanced Biliary Tract Cancer</div><h3 id="role-of-liquid-biopsy-for-detection-of-fgfr2-fusions-and-idh1-mutations-in-btc" tabindex="-1">Role of Liquid Biopsy for Detection of FGFR2 Fusions and IDH1 Mutations in BTC?</h3>
<p><img src="https://i.imgur.com/wj4hELM.png" alt="" style="height:450px;"></p>
<blockquote><p>Gouda MA, Subbiah V. Precision oncology for biliary tract tumors: it’s written in blood! Annals of Oncology. 2022;33(12):1209-1211. doi:10.1016/j.annonc.2022.09.157</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="14" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="14" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Overview" id="treatment-overview" tabindex="-1">TREATMENT: Overview</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="current"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="15" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="15" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="challenges-to-improving-outcomes-in-patients-with-btc" tabindex="-1">Challenges to Improving Outcomes in Patients With BTC</h2>
<div style="font-size: 1.8rem;">
<ul>
<li data-marpit-fragment="1">Most patients (&gt;65%) are diagnosed with unresectable disease</li>
<li data-marpit-fragment="2">Even in patients undergoing curative intent surgery, relapse rates are high (&gt;50%)</li>
<li data-marpit-fragment="3">Many patients with advanced disease are not eligible for targeted therapies as tumor profiling reveals no actionable targets</li>
<li data-marpit-fragment="4">5-yr survival rate: &lt;10% for advanced-stage disease</li>
</ul>
</div>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="16" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="16" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="timeline-of-developments-in-systemic-therapy-of-biliary-tract-cancer" tabindex="-1">Timeline of developments in systemic therapy of biliary tract cancer</h2>
<p><img src="https://i.imgur.com/W8rMXDD.png" alt="" style="height:550px;"></p>
<blockquote><p>Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. The Lancet. 2021;397(10272):428-444. doi:10.1016/S0140-6736(21)00153-7</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/NxSKKId.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="17" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<h2 id="esmo-2024" tabindex="-1">ESMO 2024</h2>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="18" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="18" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Surgery" id="treatment-surgical" tabindex="-1">Treatment: Surgical</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="current"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="19" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="19" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-52-year-old-woman" tabindex="-1">A 52-year-old woman</h2>

<p>She presents to the local ED with a 3-week history of having worsening Right upper quadrant abdominal pain. An Ultrasound is performed and suggests cholecystitis. A HIDA scan confirms that she does have <mark>cholecystitis</mark>. A General Surgeon is consulted to evaluate the patient. A <mark>cholecystectomy</mark> is recommended. She undergoes this surgery and tolerates the procedure well. On review of the Pathology report, she was incidentally found to have a <mark>T2 Gallbladder adenocarcinoma</mark> along with Cholecystitis.</p>
<p>The Medicine orders a multiphasic abdominal/pelvic CT scan along with a CT of the Chest. No other sites of disease are seen. What should be done next?</p>
<ul>
<li>A. Gemcitabine + Cisplatin</li>
<li>B. Gemcitabine-based chemoradiation</li>
<li>C. 5-FU-based chemoradiation</li>
<li>D. Take the patient for more surgery</li>
<li>E. Observation</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (D) Take the patient for more surgery</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="20" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="20" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<p><mark>If</mark> a patient undergoes surgery for Cholecystitis and is incidentally found on Pathologic review of the surgical specimen to have Gallbladder adenocarcinoma,</p>
<p><mark>then</mark> the patient needs to undergo a more definitive Oncologic surgery.</p>
<p>This is provided that the patient has been ruled out for metastatic disease.<br>
The definitive Oncologic surgery for Gallbladder cancer entails performing a <mark>hepatic resection + lymphadenectomy +/- bile duct excision</mark>.</p>
<div class="markdown-alert important" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 1.75C0 .784.784 0 1.75 0h12.5C15.216 0 16 .784 16 1.75v9.5A1.75 1.75 0 0 1 14.25 13H8.06l-2.573 2.573A1.458 1.458 0 0 1 3 14.543V13H1.75A1.75 1.75 0 0 1 0 11.25Zm1.75-.25a.25.25 0 0 0-.25.25v9.5c0 .138.112.25.25.25h2a.75.75 0 0 1 .75.75v2.19l2.72-2.72a.749.749 0 0 1 .53-.22h6.5a.25.25 0 0 0 .25-.25v-9.5a.25.25 0 0 0-.25-.25Zm7 2.25v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 9a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Important
      </span><p>More surgery is required for patients with incidentally discovered Gallbladder cancer that is <mark>T1b or greater</mark> and/or a <mark>T1a tumor with positive margins</mark>.</p>
</div><div class="markdown-alert tip" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M8 1.5c-2.363 0-4 1.69-4 3.75 0 .984.424 1.625.984 2.304l.214.253c.223.264.47.556.673.848.284.411.537.896.621 1.49a.75.75 0 0 1-1.484.211c-.04-.282-.163-.547-.37-.847a8.456 8.456 0 0 0-.542-.68c-.084-.1-.173-.205-.268-.32C3.201 7.75 2.5 6.766 2.5 5.25 2.5 2.31 4.863 0 8 0s5.5 2.31 5.5 5.25c0 1.516-.701 2.5-1.328 3.259-.095.115-.184.22-.268.319-.207.245-.383.453-.541.681-.208.3-.33.565-.37.847a.751.751 0 0 1-1.485-.212c.084-.593.337-1.078.621-1.489.203-.292.45-.584.673-.848.075-.088.147-.173.213-.253.561-.679.985-1.32.985-2.304 0-2.06-1.637-3.75-4-3.75ZM5.75 12h4.5a.75.75 0 0 1 0 1.5h-4.5a.75.75 0 0 1 0-1.5ZM6 15.25a.75.75 0 0 1 .75-.75h2.5a.75.75 0 0 1 0 1.5h-2.5a.75.75 0 0 1-.75-.75Z">
          </path>
        </svg>
        Tip
      </span><p>Hepatic resection should be performed to obtain clear margins, which usually consists of removing segments <mark>IVB and V of the liver</mark>. Lymphadenectomy should be performed to clear all lymph nodes from the porta hepatis.</p>
</div><div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p>This patient has a <mark>T2 lesion</mark> which can mean that she has up to a <mark>40%</mark> chance of harboring lymph node metastases. This patient needs a definitive surgery.</p>
</div><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="21" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="21" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-45-year-old-woman" tabindex="-1">A 45-year-old woman</h2>

<p>She presents to the local ED with a <mark>2-week history</mark> of worsening right upper quadrant abdominal pain. She presents with symptoms concerning for Cholecystitis. An Ultrasound and HIDA scan are both ordered which confirm Cholecystitis. A General Surgeon is consulted and performs a <mark>laparoscopic cholecystectomy</mark>.</p>
<p>The Pathology report is reviewed. The gallbladder was inflamed. However, she was incidentally found to have a <mark>T1a (invading the lamina propria) Gallbladder adenocarcinoma</mark>. The surgical margins are <mark>negative</mark>. A CT scan of the C/A/P with IV contrast was negative. What adjuvant therapy should be offered?</p>
<ul>
<li>A. More extensive surgery</li>
<li>B. Chemoradiation (5-FU as sensitizing chemotherapy)</li>
<li>C. FOLFOX</li>
<li>D. Gemcitabine followed by 5-FU/Radiation</li>
<li>E. Observation</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (E) Observation</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="22" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="22" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">A 45-year-old woman</div><h3 id="if-a-patient-undergoes-a-routine-cholecystectomy-for-cholecystitis-and-is-incidentally-found-to-have-a-t1a-lamina-propria" tabindex="-1">If a patient undergoes a routine cholecystectomy for cholecystitis and is incidentally found to have a T1a (lamina propria)</h3>
<div class="markdown-alert tip" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M8 1.5c-2.363 0-4 1.69-4 3.75 0 .984.424 1.625.984 2.304l.214.253c.223.264.47.556.673.848.284.411.537.896.621 1.49a.75.75 0 0 1-1.484.211c-.04-.282-.163-.547-.37-.847a8.456 8.456 0 0 0-.542-.68c-.084-.1-.173-.205-.268-.32C3.201 7.75 2.5 6.766 2.5 5.25 2.5 2.31 4.863 0 8 0s5.5 2.31 5.5 5.25c0 1.516-.701 2.5-1.328 3.259-.095.115-.184.22-.268.319-.207.245-.383.453-.541.681-.208.3-.33.565-.37.847a.751.751 0 0 1-1.485-.212c.084-.593.337-1.078.621-1.489.203-.292.45-.584.673-.848.075-.088.147-.173.213-.253.561-.679.985-1.32.985-2.304 0-2.06-1.637-3.75-4-3.75ZM5.75 12h4.5a.75.75 0 0 1 0 1.5h-4.5a.75.75 0 0 1 0-1.5ZM6 15.25a.75.75 0 0 1 .75-.75h2.5a.75.75 0 0 1 0 1.5h-2.5a.75.75 0 0 1-.75-.75Z">
          </path>
        </svg>
        Tip
      </span><p>A simple cholecystectomy is an adequate treatment for patients who are incidentally found to have <mark>T1a</mark> tumors (provided negative margins are obtained). The long-term survival rates approach 100%.</p>
</div><div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p>If a patient undergoes a routine cholecystectomy for cholecystitis and is incidentally found to have a <mark>T1a (lamina propria)</mark> Gallbladder adenocarcinoma on the surgical pathologic specimen and has achieved negative surgical margins, then the patient can undergo observation. There is no role to offer more surgery in this situation.</p>
</div><div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p>However, a patient with an incidentally discovered on cholecystectomy T1a tumor with <mark>positive</mark> surgical margins or <mark>T1b or higher</mark> adenocarcinoma will need to undergo a more definitive/radical surgery. Patients who are incidentally found to have a T1b or greater gallbladder cancer or T1a with positive margins adenocarcinoma should be offered hepatic resection + lymphadenectomy +/- bile duct excision.</p>
</div><div class="markdown-alert important" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 1.75C0 .784.784 0 1.75 0h12.5C15.216 0 16 .784 16 1.75v9.5A1.75 1.75 0 0 1 14.25 13H8.06l-2.573 2.573A1.458 1.458 0 0 1 3 14.543V13H1.75A1.75 1.75 0 0 1 0 11.25Zm1.75-.25a.25.25 0 0 0-.25.25v9.5c0 .138.112.25.25.25h2a.75.75 0 0 1 .75.75v2.19l2.72-2.72a.749.749 0 0 1 .53-.22h6.5a.25.25 0 0 0 .25-.25v-9.5a.25.25 0 0 0-.25-.25Zm7 2.25v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 9a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Important
      </span><p>These patients should then be considered for a clinical trial, observation, chemoradiation or Capecitabine <mark>preferred</mark> as adjuvant therapy.</p>
</div><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="23" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="23" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="incidental-finding-on-pathologic-review" tabindex="-1">Incidental finding on pathologic review</h2>
<p><img src="https://i.imgur.com/45YTWvj.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Gallbladder Cancer</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="24" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="24" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Chemo" id="treatment-cytotoxic-chemotherapy" tabindex="-1">TREATMENT: Cytotoxic Chemotherapy</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="current"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="25" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="25" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-62-year-old-man" tabindex="-1">A 62-year-old man</h2>

<p>recently diagnosed with stage <mark>III</mark> Gallbladder adenocarcinoma. A Surgical Oncologist performed a <mark>radical cholecystectomy</mark>, resection of segments IVB and V of his liver and lymphadenectomy. Pathologic analysis of the surgical specimen revealed a <mark>T2 N1 (Stage IIIB)</mark> Adenocarcinoma. A total of 8 lymph nodes were removed and 2 harbored cancer. The surgical resection margins are negative. CT C/A/P with IV contrast showed <mark>no evidence of distant disease</mark>. Which of the following are the preferred adjuvant treatment options for this patient?</p>
<ul>
<li>A. Fluoropyrimidine chemoradiation</li>
<li>B. Capecitabine</li>
<li>C. Clinical trial</li>
<li>D. Observation</li>
<li>E. Choices B or C</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: E, a.k.a. Choices B or C</mark></p>
<div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p data-marpit-fragment="2">If the patient in this question had lymph node metastases that were beyond the porta hepatis and/or had distant metastatic disease, then surgical resection would not have been an option.</p>
</div><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="26" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="26" style="--paginate:true;--footer:[■](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="the-swog-0809-study-provided-data-to-support-the-efficacy-of-chemoradiation-and-sequential-chemotherapy" tabindex="-1">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</h2>
<div class="half"><div>
<ul>
<li>Diagnoses: Extrahepatic Cholangiocarcinoma (EHCC) or Gallbladder Adenocarcinoma (GBCA).</li>
<li>Requirements:
<ul>
<li>Radical resection.</li>
<li>Stage pT2-4, N+, positive resection margins, M0.</li>
<li>Performance status 0 to 1.</li>
</ul>
</li>
</ul>
<hr>
<ul>
<li>Total eligible: 79 patients.
<ul>
<li>R0: 54 patients.</li>
<li>R1: 25 patients.</li>
</ul>
</li>
</ul>
</div><div>
<ul>
<li>Treatment regimen:
<ul>
<li>Chemotherapy (4 cycles):
<ul>
<li>Gemcitabine: 1,000 mg/m² IV on days 1 and 8.</li>
<li>Capecitabine: 1,500 mg/m² per day on days 1 to 14.</li>
<li>21-day cycle.</li>
</ul>
</li>
<li>Concurrent chemoradiation:
<ul>
<li>Capecitabine: 1,330 mg/m² per day.</li>
<li>Radiotherapy:
<ul>
<li>45 Gy to regional lymphatics.</li>
<li>54 to 59.4 Gy to tumor bed.</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(24):2617-2622. doi:10.1200/JCO.2014.60.2219</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="27" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="27" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</div><h3 id="outcome" tabindex="-1">Outcome</h3>
<div class="free"><div>
<p><img src="https://i.imgur.com/qJ4LkzN.png" alt="" style="height:220px;"><br>
<img src="https://i.imgur.com/pGQtF14.png" alt="" style="height:212px;"></p>
</div><div>
<ul>
<li>Survival outcomes:
<ul>
<li>2-year survival for all patients: 65% (95% CI: 53% to 74%).</li>
<li>2-year survival by resection type:
<ul>
<li>R0: 67%.</li>
<li>R1: 60%.</li>
</ul>
</li>
<li>Median overall survival:
<ul>
<li>All patients: 35 months.</li>
<li>R0: 34 months.</li>
<li>R1: 35 months.</li>
</ul>
</li>
</ul>
</li>
<li>Relapse patterns:
<ul>
<li>Local relapse: 14 patients.</li>
<li>Distant relapse: 24 patients.</li>
<li>Combined relapse: 9 patients.</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(24):2617-2622. doi:10.1200/JCO.2014.60.2219</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="28" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="28" style="--paginate:true;--footer:[■](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="capecitabine-compared-with-observation-in-resected-biliary-tract-cancer-bilcap-a-randomised-controlled-multicentre-phase-3-study" tabindex="-1">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</h2>

<ul>
<li><strong>Study Population</strong>: 447 patients with biliary tract cancers.</li>
<li><strong>Intervention</strong>: Post-surgical treatment with <strong>capecitabine</strong>.</li>
<li><strong>Key Outcomes</strong>:
<ul>
<li><strong>Survival Benefit</strong>:
<ul>
<li>Capecitabine group: <mark>Median survival = 51 months</mark> (15 months longer).</li>
<li>Observation group: Median survival = 36 months.</li>
</ul>
</li>
<li><strong>Time to Cancer Recurrence</strong>:
<ul>
<li>Capecitabine group: <mark>Median = 25 months</mark>.</li>
<li>Control group: Median = 18 months.</li>
</ul>
</li>
</ul>
</li>
<li><strong>Statistical Analysis</strong>:
<ul>
<li><strong>Overall Survival (OS)</strong>: Did not reach statistical significance in the ITT (Intent-to-Treat) analysis.</li>
</ul>
</li>
</ul>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="29" data-paginate="true" data-footer="[■](#table-of-contents)" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="29" style="--paginate:true;--footer:[■](#table-of-contents);--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</div><h3 id="efficacy" tabindex="-1">Efficacy</h3>

<ul>
<li><img src="https://i.imgur.com/PlHU071.png" alt="" style="height:500px;"></li>
<li><img src="https://i.imgur.com/wNnUFCD.png" alt="" style="height:500px;"></li>
</ul>
<blockquote><p>Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="30" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="30" style="--paginate:true;--footer:[■](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="adjuvant-s-1-jcog1202-ascot" tabindex="-1">Adjuvant S-1, JCOG1202, ASCOT</h2>
<div class="half"><div>
<p>open-label, randomised controlled, phase 3 trial</p>
<ul>
<li><strong>Patient Eligibility</strong> <i class="fa-solid fa-user-check"></i>
<ul>
<li>Aged 20–80 years</li>
<li>Histologically confirmed:
<ul>
<li>Extrahepatic cholangiocarcinoma</li>
<li>Gallbladder carcinoma</li>
<li>Ampullary carcinoma</li>
<li>Intrahepatic cholangiocarcinoma</li>
</ul>
</li>
<li>Resection criteria:
<ul>
<li>Resected specimen</li>
<li>No local residual tumour resection or microscopic residual tumour resection</li>
</ul>
</li>
</ul>
</li>
</ul>
</div><div>
<ul>
<li><strong>Randomisation</strong> <i class="fa-solid fa-random"></i>
<ul>
<li>Ratio: 1:1, Groups: Observation, S-1 treatment</li>
</ul>
</li>
<li><strong>Treatment Details (S-1 Group)</strong> <i class="fa-solid fa-pills"></i>
<ul>
<li>Dose based on body surface area:
<ul>
<li>40 mg, 50 mg, or 60 mg</li>
</ul>
</li>
<li>Administration:
<ul>
<li>Orally twice daily</li>
<li>4 weeks of treatment followed by 2 weeks of rest</li>
<li>Total: Four cycles</li>
</ul>
</li>
</ul>
</li>
<li><strong>Endpoints</strong> <i class="fa-solid fa-chart-line"></i>
<ul>
<li>Primary: Overall survival</li>
<li>Assessment: Intention-to-treat basis</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England). 2023;401(10372):195-203. doi:10.1016/S0140-6736(22)02038-4</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/1VJzGgM.png&quot;);background-size:auto 600px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="31" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">Adjuvant S-1, JCOG1202, ASCOT</div><h3 id="efficacy-1" tabindex="-1">Efficacy</h3>
<table>
<thead>
<tr>
<th>Group</th>
<th>3-Year OS (%)</th>
<th>Adjusted HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-1</td>
<td>77.1</td>
<td>0.69 (0.51–0.94)</td>
<td>0.0080 (one-sided)</td>
</tr>
<tr>
<td>Observation</td>
<td>67.6 (61.0–73.3)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<br>
<table>
<thead>
<tr>
<th>Group</th>
<th>3-Year RFS (%)</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-1</td>
<td>62.4</td>
<td>0.80 (0.61–1.04)</td>
<td>0.088 (two-sided)</td>
</tr>
<tr>
<td>Observation</td>
<td>50.9 (44.1–57.2)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<ul>
<li>Main Grade 3–4 Adverse Events:<br>
- Decreased Neutrophil Count: 14% (29 patients)<br>
- Biliary Tract Infection: 7% (15 patients)</li>
</ul>
<blockquote><p>Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England). 2023;401(10372):195-203. doi:10.1016/S0140-6736(22)02038-4</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="32" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="32" style="--paginate:true;--footer:[■](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="frontline-treatment-of-advanced-btc-abc-02" tabindex="-1">Frontline Treatment of Advanced BTC: ABC-02</h2>

<ul>
<li>
<p>Objective: Evaluate the efficacy of cisplatin plus gemcitabine versus gemcitabine alone in advanced biliary tract cancers.</p>
</li>
<li>
<p>Participants:</p>
<ul>
<li>Total: 410 patients.</li>
<li>Conditions: Locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer.</li>
</ul>
</li>
<li>
<p>Treatment Groups:</p>
<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment Details</th>
<th>Schedule</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin + Gemcitabine</td>
<td>Cisplatin: 25 mg/m² <br> Gemcitabine: 1000 mg/m²</td>
<td>Days 1 and 8, every 3 weeks</td>
<td>8 cycles</td>
</tr>
<tr>
<td>Gemcitabine Alone</td>
<td>Gemcitabine: 1000 mg/m²</td>
<td>Days 1, 8, and 15, every 4 weeks</td>
<td>6 cycles</td>
</tr>
</tbody>
</table>
</li>
</ul>
<blockquote><p>Valle J. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine. April 8, 2010. Accessed January 9, 2025. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0908721">https://www.nejm.org/doi/full/10.1056/NEJMoa0908721</a></p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:35%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/R5C9POo.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="65%" height="720"><section id="33" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:35%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">Frontline Treatment of Advanced BTC: ABC-02</div><h3 id="results" tabindex="-1">Results</h3>
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Cisplatin + Gemcitabine</th>
<th>Gemcitabine Alone</th>
<th>P-value</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival (Median)</td>
<td>11.7 months</td>
<td>8.1 months</td>
<td>&lt; 0.001</td>
<td>Hazard Ratio: 0.64</td>
</tr>
<tr>
<td>Progression-Free Survival</td>
<td>8.0 months</td>
<td>5.0 months</td>
<td>&lt; 0.001</td>
<td>-</td>
</tr>
<tr>
<td>Tumor Control Rate</td>
<td>81.4%</td>
<td>71.8%</td>
<td>0.049</td>
<td>Cisplatin + Gemcitabine significantly improved rates</td>
</tr>
</tbody>
</table>
<h4 id="conclusion" tabindex="-1">Conclusion</h4>
<ul>
<li>The combination of cisplatin and gemcitabine significantly improved overall survival, progression-free survival, and tumor control compared to gemcitabine alone in patients with advanced biliary tract cancers.</li>
</ul>
<blockquote><p>Valle J. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine. April 8, 2010. Accessed January 9, 2025. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0908721">https://www.nejm.org/doi/full/10.1056/NEJMoa0908721</a></p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="--paginate:true;--footer:[■](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/f4gPEmW.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="34" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="--paginate:true;--footer:[■](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>1L mBTC</header>
<h2 id="tc1308" tabindex="-1">TC1308</h2>
<p>phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer, including IHCC, EHCC, GBC, and AVC</p>
<p><img src="https://i.imgur.com/xiWqAVL.png" alt="" style="height:450px;"></p>
<blockquote><p>Chiang NJ, Chen MH, Yang SH, et al. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver international : official journal of the International Association for the Study of the Liver. 2020;40(10):2535-2543. doi:10.1111/liv.14538</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/JwBvLPg.png&quot;);background-size:auto 550px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="35" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content"><blockquote><p>TCOG. 研發台灣膽道癌專屬免疫化療複方(NGS) 降低副作用 整體存活期延長至 19 個月 – National Institute of Cancer Research. Accessed January 13, 2025. <a href="https://nicr.nhri.edu.tw/en/110221press/">https://nicr.nhri.edu.tw/en/110221press/</a></p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="36" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="36" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L mBTC</header>
<h2 id="folfox-in-btc-abc-06" tabindex="-1">FOLFOX in BTC (ABC-06)</h2>
<div class="free"><div>
<ul>
<li><strong>Histologically or cytologically verified</strong>: Locally advanced or metastatic biliary tract cancer.</li>
<li><strong>Documented progression</strong>: Radiological evidence of disease progression following first-line cisplatin and gemcitabine chemotherapy.</li>
<li><strong>ECOG Performance Status</strong>: Score of 0–1.</li>
<li><strong>Randomization</strong>: Participants randomly assigned (1:1) to:
<ul>
<li>Active symptom control (ASC) + FOLFOX.</li>
<li>ASC alone.</li>
</ul>
</li>
<li><strong>FOLFOX Administration</strong>:
<ul>
<li>Administered <strong>intravenously</strong> every <strong>2 weeks</strong>.</li>
<li>Maximum of <strong>12 cycles</strong>.</li>
</ul>
</li>
</ul>
</div><div>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase</td>
<td>3</td>
</tr>
<tr>
<td>Trial Type</td>
<td>Randomised</td>
</tr>
<tr>
<td>Location</td>
<td>UK</td>
</tr>
<tr>
<td>Patient Age</td>
<td>≥18 years</td>
</tr>
<tr>
<td>Cancer Type</td>
<td>Biliary</td>
</tr>
<tr>
<td>Performance</td>
<td>0–1</td>
</tr>
<tr>
<td>Treatment</td>
<td>FOLFOX</td>
</tr>
<tr>
<td>Primary Endpoint</td>
<td>Survival</td>
</tr>
</tbody>
</table>
</div></div>

<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/mZU0gE0.png&quot;);background-size:auto 500px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="37" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">FOLFOX in BTC (ABC-06)</div><h3 id="efficacy-2" tabindex="-1">Efficacy</h3>
<p><img src="https://i.imgur.com/thbONbf.png" alt="" style="height:400px;"></p>
<p>ABC-06 study show that FOLFOX can improve OS with advanced biliary tract cancer who have been previously treated with cisplatin and gemcitabine.</p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="38" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="38" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="ICI" id="treatment-immunotherapy" tabindex="-1">TREATMENT: Immunotherapy</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="current"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="39" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="39" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-64-year-old-woman-with-metastatic-gallbladder-cancer" tabindex="-1">A 64-year-old woman with metastatic gallbladder cancer</h2>

<p>A CT scan of the C/A/P with IV contrast showed disease in her gallbladder along with several liver lesions.<br>
A biopsy of a liver lesion was performed. Pathology confirmed metastatic gallbladder cancer</p>
<p>A CMP reveals that her direct bilirubin is 4 mg/dl.<br>
A liver lesion is causing obstruction of a bile duct. She undergoes an ERCP with stent placement. Her hyperbilirubinemia resolved. She is not interested in a clinical trial. She has an outstanding performance status. NGS not reveal any actionable mutations. <mark>The tumor is MSS and TMB low</mark></p>
<p><strong>Which of the following treatment regimens should be offered?</strong></p>
<ul>
<li>A. Gemcitabine + 5-FU</li>
<li>B. FOLFIRINOX</li>
<li>C. Gemcitabine + Nab-Paclitaxel</li>
<li>D. Gemcitabine + Cisplatin + Durvalumab</li>
<li>E. Pembrolizumab</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: (D) Gemcitabine + Cisplatin + Durvalumab</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="40" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="40" style="--paginate:true;--footer:[■](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="topaz-1-durvalumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc" tabindex="-1">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</h2>

<p><img src="https://i.imgur.com/BTMZcXl.png" alt="" style="height:450px;"></p>
<blockquote><p>Burris. ASCO 2022. Abstr 4070. Oh. ASCO GI 2022. Abstr 378.</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="41" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="41" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</div><h3 id="results-1" tabindex="-1">Results</h3>
<p><img src="https://i.imgur.com/IVPYsSe.jpeg" alt="" style="height:550px;"></p>
<blockquote><p>Burris. ASCO 2022. Abstr 4070. Oh. ASCO GI 2022. Abstr 378.</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="42" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="42" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-54-year-old-man" tabindex="-1">A 54-year-old man</h2>

<p>A 54-year-old man  with no significant past medical history has been recently diagnosed with <mark>Stage IV Extrahepatic Cholangiocarcinoma</mark> CT imaging of the Chest/Abdomen/Pelvis revealed bilateral <mark>liver and lung metastases</mark>. There is also a mass seen in the extrahepatic bile duct.</p>
<p>Interventional Radiology performs a biopsy of a lung lesion that confirms the diagnosis. <mark>NGS testing of the tumor reveals no actionable mutations</mark>. The tumor is <mark>MSS and TMB low</mark>. Which of the following immunotherapy medications can be given alongside Gemcitabine + Cisplatin as part of frontline treatment?</p>
<ul>
<li>A. Nivolumab</li>
<li>B. Pembrolizumab</li>
<li>C. Atezolizumab</li>
<li>D. Ipilimumab</li>
<li>E. Toripalimab</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (B) Pembrolizumab, mOS was 12.7 months vs 10.9 months</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="43" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="43" style="--paginate:true;--footer:[■](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="keynote-966-pembrolizumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc" tabindex="-1">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</h2>

<p><img src="https://i.imgur.com/B5YnRtd.png" alt="" style="height:450px;"></p>
<blockquote><p>Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Gkmty15.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="35%" height="720"><section id="44" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</div><h3 id="efficacy-3" tabindex="-1">Efficacy</h3>
<p><img src="https://i.imgur.com/zcIgxhR.png" alt="" style="height:150px;"></p>
<p>The median OS was <mark>12.7 months</mark> (95% CI: 11.5, 13.6) and <mark>10.9 months</mark> (95% CI: 9.9, 11.6) in the respective arms.</p>
<blockquote><p>Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="45" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="45" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="what-did-we-learn-from-topaz-1-and-keynote-966" tabindex="-1">What did we learn from TOPAZ-1 and KEYNOTE-966</h2>
<table>
<thead>
<tr>
<th>Aspect</th>
<th>TOPAZ-1</th>
<th>KEYNOTE-966</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>685 patients</td>
<td>1,069 patients</td>
</tr>
<tr>
<td>Overall Survival (OS)</td>
<td>12.8 vs. 11.5 months (HR=0.80, P=0.021)</td>
<td>12.7 vs. 10.9 months (HR=0.83, P=0.0034)</td>
</tr>
<tr>
<td>Progression-Free Survival (PFS)</td>
<td>Improved (exact numbers not specified)</td>
<td>6.5 vs. 5.6 months (P=0.023)</td>
</tr>
<tr>
<td>Subgroup Representativeness</td>
<td>More representation from Asia, less intrahepatic tumors</td>
<td>Higher intrahepatic tumor cases, more patients from outside Asia (55%)</td>
</tr>
<tr>
<td>Chemotherapy Duration</td>
<td>Chemotherapy discontinued after 8 cycles; Durvalumab continued in the intervention arm</td>
<td>Chemotherapy continued longer (up to best response)</td>
</tr>
<tr>
<td>Immune-Mediated Adverse Events</td>
<td>Any grade: 12.7% (Durvalumab) vs. 4.7% (Placebo); Grade 3/4: 2.4% vs. 1.5%</td>
<td>Any grade: 22% (Pembrolizumab) vs. 13% (Placebo); Grade 3/4: 7% vs. 4%</td>
</tr>
<tr class="emphasize">
<td><strong>PD-L1 Combined Positive Score (CPS)</strong></td>
<td>Benefits observed regardless of CPS levels</td>
<td>Benefits observed regardless of CPS levels</td>
</tr>
<tr>
<td>Geographic Distribution</td>
<td>Higher proportion of Asian participants</td>
<td>More globally distributed; 55% of participants outside Asia</td>
</tr>
<tr class="emphasize">
<td><strong>Tumor Subtype Coverage</strong></td>
<td>Benefits seen in both intrahepatic and extrahepatic tumors</td>
<td>Benefits more pronounced in intrahepatic tumors</td>
</tr>
</tbody>
</table>
<blockquote><p>Almhanna K. Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966. Translational Cancer Research. 13(1). doi:10.21037/tcr-23-1763</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="46" data-paginate="true" data-footer="[■](#table-of-contents)" data-class="flexImg" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="46" style="--paginate:true;--footer:[■](#table-of-contents);--class:flexImg;--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="gemcitabine-and-s-1-plus-nivolumab-in-advanced-biliary-tract-cancer-a-phase-ii-t1219-study" tabindex="-1">Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study</h2>

<p><mark>NGS</mark> nivolumab 240 mg and 800 mg/m2 gemcitabine on day 1 plus daily 80/100/120 mg of S-1 (based on body surface area) on days 1 to 10, in a 2-week cycle.</p>
<ul>
<li><img src="https://i.imgur.com/Hv1piC8.png" alt="" style="height:400px;"></li>
<li><img src="https://i.imgur.com/s1BnTeK.png" alt="" style="height:400px;"></li>
</ul>
<blockquote><p>Chiang NJ, Tan KT, Bai LY, et al. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical Cancer Research. 2022;28(19):4248-4257. doi:10.1158/1078-0432.CCR-22-1152</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="47" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="47" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Target" id="treatment-target" tabindex="-1">TREATMENT: Target</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="before"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="current"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="48" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="48" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="esmo-2024-1" tabindex="-1">ESMO 2024</h2>
<p><img src="https://i.imgur.com/dhf9tqS.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="49" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="49" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-72-year-old-man" tabindex="-1">A 72-year-old man</h2>

<p>A 72-year-old man to start second-line treatment for his metastatic gallbladder cancer. He was diagnosed with metastatic gallbladder cancer 1 year ago.</p>
<p>A baseline CT C/A/P revealed bilateral <mark>liver metastases along with a gallbladder mass</mark>. At that time, he underwent a palliative cholecystectomy due to severe right upper quadrant pain. Pathologic analysis of the surgical specimen revealed Gallbladder adenocarcinoma.</p>
<p>He was started on palliative chemotherapy with <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response that lasted for one year prior to disease progression. NGS testing of his tumor revealed an <mark>FGFR2 fusion</mark>. His performance status remains robust outside of Grade I neuropathy that is from his prior exposure to Cisplatin. Which therapy should be recommended?</p>
<ul>
<li>A. Hospice</li>
<li>B. FOLFIRINOX</li>
<li>C. Nivolumab</li>
<li>D. Nab-Paclitaxel</li>
<li>E. Pemigatinib</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: E, Pemigatinib</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="50" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="50" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="approved-fgfr-inhibitors-for-advanced-cholangiocarcinoma-key-phase-ii-trials" tabindex="-1">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</h2>

<p><img src="https://i.imgur.com/Oz9unrE.png" alt="" style="height:450px;"></p>
<blockquote><p>Abou-Alfa. Lancet Oncol. 2020;21:671. Goyal. NEJM. 2023;388:228. Pemigatinib PI. Futibatinib PI.</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="51" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="51" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<div class="h2text firsth3afterh2">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</div><h3 id="nhi" tabindex="-1">NHI</h3>
<ul>
<li>Pemigatinib （如 Pemazyre）：(112/5/1、113/6/1)
<ol>
<li>適用於成人接受過全身性藥物治療、腫瘤具有 FGFR2 融合或重排、不可手術切除的局部晚期或轉移性肝內膽管癌。</li>
<li>需經事前審查核准後使用，初次申請需檢附腫瘤組織具有 FGFR2 基因融合或重排之基因變異檢測報告，且需符合全民健康保險藥品給付規定之通則十二。(113/6/1)</li>
<li>核准後每 12 週需再次申請，再次申請時需檢附療效評估資料證實無疾病惡化，才可繼續使用。</li>
<li>每日限處方 1 粒。</li>
</ol>
</li>
</ul>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="52" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="52" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<div class="h2text">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</div><h3 id="a-78-year-old-feman-iv-intrahepatic-bile-duct-cancer" tabindex="-1">A 78-year-old feman, IV Intrahepatic bile duct cancer</h3>

<p>Next generation sequencing of the tumor was performed and revealed an <mark>FGFR2 fusion</mark>.<br>
She was <mark>treated with Gemcitabine, Cisplatin and Durvalumab x 6 cycles</mark> and she had a near complete response. She was then placed on maintenance therapy with Gemcitabine + Durvalumab. She had stable disease that lasted for 18 months prior to disease progression. She tolerated therapy well but has <mark>residual neuropathy from Cisplatin</mark>. While she would <mark>like to continue therapy</mark>, she would like to avoid medications that may cause worsening of her neuropathy. Which therapy should be offered?</p>
<ul>
<li>A. Futibatinib</li>
<li>B. Pemigatinib</li>
<li>C. Regorafenib</li>
<li>D. Choices A or B</li>
<li>E. All of the above</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: D, Choices A or B</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="53" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="53" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="fgfr-inhibitors-unique-class-specific-adverse-events" tabindex="-1">FGFR Inhibitors: Unique Class-Specific Adverse Events</h2>

<p><img src="https://i.imgur.com/P37IaVI.jpeg" alt="" style="height:420px;"></p>
<div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p><mark>Hyperphosphatemia</mark> is the most common AE<br>
All patients should have a baseline <mark>eye exam</mark> before therapy initiation</p>
</div><blockquote><p>Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer treatment reviews. 2021;95:102170. doi:10.1016/j.ctrv.2021.102170</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="54" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-class="flexList" data-heading-divider="3" data-theme="main" lang="en-US" class="flexList" data-marpit-pagination="54" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--class:flexList;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="idh1-mutations-in-icc" tabindex="-1">IDH1 Mutations in ICC</h2>

<p>68-year-old man, metastatic bile duct cancer.<br>
At that time, he was started on <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response.<br>
He was then started on treatment with <mark>FOLFOX</mark>. He had another partial response that lasted for 1 year prior to disease progression.<br>
A recent restaging CT scan of the C/A/P shows two new liver lesions.</p>

<ul>
<li>
<p>Next Generation Sequencing of the tumor reveals the following:</p>
<ul>
<li>No FGFR2 fusion, No NTRK gene fusion</li>
<li>No BRAF mutation</li>
<li>MSS, TMB low</li>
<li><mark>IDH1 mutated</mark></li>
</ul>
</li>
<li>
<p>Which treatment should be offered?</p>
<ul>
<li>A. Enasidenib</li>
<li>B. Ivosidenib</li>
<li>C. Regorafenib</li>
<li>D. Lenalidomide</li>
<li>E. Futibatinib</li>
</ul>
</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: B</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="55" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="55" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="claridhy-ivosidenib-vs-placebo-in-previously-treated-cholangiocarcinoma-with-idh1-mutation" tabindex="-1">ClarIDHy: Ivosidenib vs Placebo in Previously Treated Cholangiocarcinoma With <mark>IDH1</mark> Mutation</h2>

<p>An international, double-blind, randomized phase III trial</p>
<p><img src="https://i.imgur.com/mtnjSdF.png" alt="" style="height:450px;"></p>
<blockquote><p>Abou-Alfa. Lancet Oncol. 2020;21:796. Zhu. JAMA Oncol. 2021;e213836.</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="56" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="56" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-75-year-old-feman" tabindex="-1">A 75-year-old feman</h2>

<p>start second-line therapy for her Metastatic extrahepatic cholangiocarcinoma. She was started on frontline therapy with Cisplatin + Gemcitabine + Pembrolizumab. She had a partial response to treatment that lasted for 6 months prior to disease progression. Due to the side effects that she endured from chemotherapy, she is not interested in being treated with this class of medication going forward.</p>
<p>A recent restaging scan showed enlargement of her known liver lesions and the development of new lung lesions. A repeat biopsy of a liver lesion is performed that confirms Cholangiocarcinoma. Next Generation Sequencing is sent for on this tumor sample. <mark>A BRAF V600E mutation is seen</mark>. The only other mutation seen is a TP53 mutation. The patient does have a robust performance status. Which therapy is the best regimen to start at this time?</p>
<ul>
<li>A. FOLFOX</li>
<li>B. Lenvatinib + Pembrolizumab</li>
<li>C. Dabrafenib + Trametinib</li>
<li>D. Vemurafenib + Cobimetinib</li>
<li>E. Pralsetinib</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (C) Dabrafenib + Trametinib</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="57" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="57" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="dabrafenib--trametinib-for-brafv600e%E2%80%93mutated-btc-tumor-size-change-and-response-duration" tabindex="-1">Dabrafenib + Trametinib for BRAF<sup>V600E</sup>–Mutated BTC: Tumor Size Change and Response Duration</h2>

<p><mark>ROAR</mark>: phase 2, open-label, single-arm, multicentre basket trial</p>

<ul>
<li><img src="https://i.imgur.com/hWIC0b8.png" alt="" style="height:350px;"></li>
<li><img src="https://i.imgur.com/LShcibZ.png" alt="" style="height:350px;"></li>
</ul>
<blockquote><p>Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. The Lancet Oncology. 2020;21(9):1234-1243. doi:10.1016/S1470-2045(20)30321-1</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="58" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="Case Challenge" data-class="flexList" data-heading-divider="3" data-theme="main" lang="en-US" class="flexList" data-marpit-pagination="58" style="--paginate:true;--footer:[■](#table-of-contents);--header:Case Challenge;--class:flexList;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-74-year-old-man" tabindex="-1">A 74-year-old man</h2>

<p>One year ago, he was diagnosed with <mark>Stage IV disease</mark>. The tumor originated in his gallbladder. A baseline CT C/A/P with IV contrast showed bilateral liver metastases along with 4 pulmonary lesions. A biopsy of a lung lesion confirmed bile duct cancer. <mark>Testing of the tumor revealed that the Her2=3+ on IHC</mark>.</p>
<p>s/p <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response to treatment that lasted for 1 year prior to disease progression. The Cisplatin was stopped after 6 cycles of therapy as he developed Grade 2 neuropathy. The patient was placed on maintenance therapy with Gemcitabine + Durvalumab.</p>

<ul>
<li>NGS testing of the tumor revealed the following:
<ul>
<li>No FGFR2 fusion</li>
<li>No NTRK gene fusion, No RET gene fusion</li>
<li>BRAF wild-type, IDH1 wild-type</li>
<li>TMB: Low MSS</li>
</ul>
</li>
<li>For second-line therapy, what should be offered?
<ul>
<li>A. FOLFOXIRI</li>
<li>B. Regorafenib</li>
<li>C. Paclitaxel + Ramucirumab</li>
<li>D. Trastuzumab deruxtecan</li>
<li>E. FOLFOX + Trastuzumab</li>
</ul>
</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (D) Trastuzumab deruxtecan</mark></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="59" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="59" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="destiny-pantumor02-phase-ii-trial" tabindex="-1">DESTINY-PanTumor02 Phase II Trial</h2>

<p><img src="https://i.imgur.com/m9KHVGH.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="60" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="60" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<div class="h2text firsth3afterh2">DESTINY-PanTumor02 Phase II Trial</div><h3 id="outcome-1" tabindex="-1">Outcome</h3>

<ul>
<li><img src="https://i.imgur.com/QK7FLJT.png" alt="" style="height:450px;"></li>
<li><img src="https://i.imgur.com/EoOv2uV.png" alt="" style="height:450px;"></li>
</ul>
<blockquote><p>Meric-Bernstam F. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology. Published online January 1, 2024.</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Us4tXYh.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="61" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>2L+ mBTC</header>
<h2 id="zanidatamab-zw25-a-humanized-igg1-like-biparatopic-antibody" tabindex="-1">Zanidatamab (ZW25): A Humanized IgG1-like Biparatopic Antibody</h2>

<ul>
<li>Zanidatamab is a HER2-targeted bispecific antibody that binds 2 separate HER2 epitopes, resulting in multiple mechanisms of action</li>
<li>Zanidatamab binds 2 HER2 domains targeted by trastuzumab (ECD4) and pertuzumab (ECD2)</li>
<li>Cross links multiple HER2 receptors</li>
<li>Improves HER2 internalization and degradation</li>
<li>Preclinical studies showed growth inhibition of cancer cell lines with wide range of HER2 expression</li>
</ul>
<blockquote><p>Weisser. Nature Commun. 2023;14:1394. Tarantino. Explor Antitumor Ther. 2021;2:139. DiPeri. Cancer Discov. 2024;[Epub].</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:45%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/IHmkAkr.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="55%" height="720"><section id="62" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:45%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>2L+ mBTC</header>
<h2 id="herizon-btc-01-zanidatamab-for-previously-treated-her2%E2%80%90amplified-biliary-tract-cancer" tabindex="-1">HERIZON-BTC-01: Zanidatamab for Previously Treated HER2‐Amplified Biliary Tract Cancer</h2>
<p><img src="https://i.imgur.com/6C1lHpI.png" alt="" style="height:300px;"></p>

<p><img class="emoji" draggable="false" alt="👀" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@15.1.0/assets/svg/1f440.svg" data-marp-twemoji=""> HERIZON-BTC-302: First-Line Zanidatamab + SoC Therapy for Patients With Advanced HER2+ BTC</p>
<blockquote><p>Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet Oncology. 2023;24(7):772-782. doi:10.1016/S1470-2045(23)00242-5</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="63" data-paginate="true" data-footer="[■](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="63" style="--paginate:true;--footer:[■](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="incidence-of-therapeutic-targets-in-advanced-biliary-tract-cancers" tabindex="-1">Incidence of Therapeutic Targets in Advanced Biliary Tract Cancers</h2>
<p><img src="https://i.imgur.com/Xpud4I2.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="64" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="64" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 id="takeaway" tabindex="-1">Takeaway</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="before"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="before"><a href="#treatment-target">TREATMENT: Target</a></li><li class="current"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="65" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="65" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="precision-oncology-is-key-for-management-of-advanced-cholangiocarcinoma" tabindex="-1">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</h2>
<p><img src="https://i.imgur.com/NVsMu4z.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/0IqaIuN.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="66" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content"><footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/ZtIKKw1.png&quot;);background-size:auto 550px;"></figure><figure style="background-image:url(&quot;https://i.imgur.com/I3m9pCu.png&quot;);background-size:auto 550px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="67" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text firsth3afterh2">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="early-stage" tabindex="-1">Early Stage</h3>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/raSeYZo.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="68" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="advanced-or-metastatic-stage" tabindex="-1">Advanced or Metastatic Stage</h3>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/rDbUGc4.png&quot;);background-size:auto 350px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="69" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="advanced-or-metastatic-stage-relapse-and-refractory" tabindex="-1">Advanced or Metastatic Stage: relapse and refractory</h3>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="70" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="70" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="tldr" tabindex="-1">TL;DR</h2>
<br>
<table>
<thead>
<tr>
<th>分類</th>
<th>現行國際標準治療</th>
<th>其他新療法</th>
</tr>
</thead>
<tbody>
<tr>
<td>第一線</td>
<td>1. GC 處方（健保給付）：<br>gemcitabine（健療）+ cisplatin（順鉑）</td>
<td>1. GC 處方 + durvalumab</td>
</tr>
<tr>
<td></td>
<td>2. 改良型 GS 處方（TS-1 需自費）：<br>gemcitabine（健療）+ 愛斯施達（TS-1）</td>
<td>2. GS 處方 + nivolumab</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. GC 處方 + pembrolizumab</td>
</tr>
<tr>
<td>第二線</td>
<td>FOLFOX（5-FU/leucovorin/oxaliplatin）（oxaliplatin 需自費）</td>
<td>- IDH 基因變異可用 TIBSOVO（ivosidenib 錠劑）</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- FGFR2 基因融合/重排者：<br>pemigatinib（第二線健保暫時性給付），infigratinib，futibatinib</td>
</tr>
</tbody>
</table>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="71" data-paginate="true" data-footer="[■](#table-of-contents)" data-class="center" data-heading-divider="3" data-theme="main" lang="en-US" class="center" data-marpit-pagination="71" style="--paginate:true;--footer:[■](#table-of-contents);--class:center;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 class="animated-text" id="thank-you" tabindex="-1">Thank you</h2>
<hr>
<h5 is="marp-h5" data-auto-scaling="" id="advancements-in-cholangiocarcinoma-treatment-1" tabindex="-1">Advancements in Cholangiocarcinoma Treatment</h5>
<hr>
<h4 id="lets-take-some-questions" tabindex="-1">Let’s Take Some Questions</h4>
<footer><a href="#table-of-contents">■</a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="72" data-paginate="true" data-footer="[■](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="72" style="--paginate:true;--footer:[■](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="table-of-contents" tabindex="-1">Table of Contents</h2>
<p></p><div class="table-of-contents"><ul><li><a href="#advancements-in-cholangiocarcinoma-treatment">Advancements in Cholangiocarcinoma Treatment</a></li><li><a href="#case">Case</a><ul><li><a href="#72-year-old-man---06103741">72-year-old man - 06103741</a></li></ul></li><li><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a><ul><li><a href="#characteristics-and-anatomical-features-of-biliary-tract-cancers">Characteristics and Anatomical Features of Biliary Tract Cancers</a></li><li><a href="#presentation-and-workup">Presentation and Workup</a></li><li><a href="#btc-staging-per-ajcc-8th">BTC Staging, per AJCC 8th</a></li><li><a href="#molecular-testing-in-advanced-biliary-tract-cancer">Molecular Testing in Advanced Biliary Tract Cancer</a></li></ul></li><li><a href="#treatment-overview">TREATMENT: Overview</a><ul><li><a href="#challenges-to-improving-outcomes-in-patients-with-btc">Challenges to Improving Outcomes in Patients With BTC</a></li><li><a href="#timeline-of-developments-in-systemic-therapy-of-biliary-tract-cancer">Timeline of developments in systemic therapy of biliary tract cancer</a></li><li><a href="#esmo-2024">ESMO 2024</a></li></ul></li><li><a href="#treatment-surgical">Treatment: Surgical</a><ul><li><a href="#a-52-year-old-woman">A 52-year-old woman</a></li><li><a href="#a-45-year-old-woman">A 45-year-old woman</a></li><li><a href="#incidental-finding-on-pathologic-review">Incidental finding on pathologic review</a></li></ul></li><li><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a><ul><li><a href="#a-62-year-old-man">A 62-year-old man</a></li><li><a href="#the-swog-0809-study-provided-data-to-support-the-efficacy-of-chemoradiation-and-sequential-chemotherapy">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</a></li><li><a href="#capecitabine-compared-with-observation-in-resected-biliary-tract-cancer-bilcap-a-randomised-controlled-multicentre-phase-3-study">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</a></li><li><a href="#adjuvant-s-1-jcog1202-ascot">Adjuvant S-1, JCOG1202, ASCOT</a></li><li><a href="#frontline-treatment-of-advanced-btc-abc-02">Frontline Treatment of Advanced BTC: ABC-02</a></li><li><a href="#tc1308">TC1308</a></li><li><a href="#folfox-in-btc-abc-06">FOLFOX in BTC (ABC-06)</a></li></ul></li><li><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a><ul><li><a href="#a-64-year-old-woman-with-metastatic-gallbladder-cancer">A 64-year-old woman with metastatic gallbladder cancer</a></li><li><a href="#topaz-1-durvalumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</a></li><li><a href="#a-54-year-old-man">A 54-year-old man</a></li><li><a href="#keynote-966-pembrolizumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</a></li><li><a href="#what-did-we-learn-from-topaz-1-and-keynote-966">What did we learn from TOPAZ-1 and KEYNOTE-966</a></li><li><a href="#gemcitabine-and-s-1-plus-nivolumab-in-advanced-biliary-tract-cancer-a-phase-ii-t1219-study">Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study</a></li></ul></li><li><a href="#treatment-target">TREATMENT: Target</a><ul><li><a href="#esmo-2024-1">ESMO 2024</a></li><li><a href="#a-72-year-old-man">A 72-year-old man</a></li><li><a href="#approved-fgfr-inhibitors-for-advanced-cholangiocarcinoma-key-phase-ii-trials">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</a></li><li><a href="#fgfr-inhibitors-unique-class-specific-adverse-events">FGFR Inhibitors: Unique Class-Specific Adverse Events</a></li><li><a href="#idh1-mutations-in-icc">IDH1 Mutations in ICC</a></li><li><a href="#claridhy-ivosidenib-vs-placebo-in-previously-treated-cholangiocarcinoma-with-idh1-mutation">ClarIDHy: Ivosidenib vs Placebo in Previously Treated Cholangiocarcinoma With IDH1 Mutation</a></li><li><a href="#a-75-year-old-feman">A 75-year-old feman</a></li><li><a href="#dabrafenib--trametinib-for-brafv600e%E2%80%93mutated-btc-tumor-size-change-and-response-duration">Dabrafenib + Trametinib for BRAFV600E–Mutated BTC: Tumor Size Change and Response Duration</a></li><li><a href="#a-74-year-old-man">A 74-year-old man</a></li><li><a href="#destiny-pantumor02-phase-ii-trial">DESTINY-PanTumor02 Phase II Trial</a></li><li><a href="#zanidatamab-zw25-a-humanized-igg1-like-biparatopic-antibody">Zanidatamab (ZW25): A Humanized IgG1-like Biparatopic Antibody</a></li><li><a href="#herizon-btc-01-zanidatamab-for-previously-treated-her2%E2%80%90amplified-biliary-tract-cancer">HERIZON-BTC-01: Zanidatamab for Previously Treated HER2‐Amplified Biliary Tract Cancer</a></li><li><a href="#incidence-of-therapeutic-targets-in-advanced-biliary-tract-cancers">Incidence of Therapeutic Targets in Advanced Biliary Tract Cancers</a></li></ul></li><li><a href="#takeaway">Takeaway</a><ul><li><a href="#precision-oncology-is-key-for-management-of-advanced-cholangiocarcinoma">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</a></li><li><a href="#tldr">TL;DR</a></li><li><a href="#thank-you">Thank you</a></li><li><a href="#table-of-contents">Table of Contents</a></li></ul></li></ul></div><p></p>
<footer><a href="#table-of-contents">■</a></footer>
</section>
<script>!function(){"use strict";const t={h1:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"1"},style:"display: block; font-size: 2em; margin-block-start: 0.67em; margin-block-end: 0.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h2:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"2"},style:"display: block; font-size: 1.5em; margin-block-start: 0.83em; margin-block-end: 0.83em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h3:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"3"},style:"display: block; font-size: 1.17em; margin-block-start: 1em; margin-block-end: 1em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h4:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"4"},style:"display: block; margin-block-start: 1.33em; margin-block-end: 1.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h5:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"5"},style:"display: block; font-size: 0.83em; margin-block-start: 1.67em; margin-block-end: 1.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h6:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"6"},style:"display: block; font-size: 0.67em; margin-block-start: 2.33em; margin-block-end: 2.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},span:{proto:()=>HTMLSpanElement},pre:{proto:()=>HTMLElement,style:"display: block; font-family: monospace; white-space: pre; margin: 1em 0; --marp-auto-scaling-white-space: pre;"}},e="data-marp-auto-scaling-wrapper",i="data-marp-auto-scaling-svg",n="data-marp-auto-scaling-container";class s extends HTMLElement{container;containerSize;containerObserver;svg;svgComputedStyle;svgPreserveAspectRatio="xMinYMid meet";wrapper;wrapperSize;wrapperObserver;constructor(){super();const t=t=>([e])=>{const{width:i,height:n}=e.contentRect;this[t]={width:i,height:n},this.updateSVGRect()};this.attachShadow({mode:"open"}),this.containerObserver=new ResizeObserver(t("containerSize")),this.wrapperObserver=new ResizeObserver(((...e)=>{t("wrapperSize")(...e),this.flushSvgDisplay()}))}static get observedAttributes(){return["data-downscale-only"]}connectedCallback(){this.shadowRoot.innerHTML=`\n<style>\n  svg[${i}] { display: block; width: 100%; height: auto; vertical-align: top; }\n  span[${n}] { display: table; white-space: var(--marp-auto-scaling-white-space, nowrap); width: max-content; }\n</style>\n<div ${e}>\n  <svg part="svg" ${i}>\n    <foreignObject><span ${n}><slot></slot></span></foreignObject>\n  </svg>\n</div>\n    `.split(/\n\s*/).join(""),this.wrapper=this.shadowRoot.querySelector(`div[${e}]`)??void 0;const t=this.svg;this.svg=this.wrapper?.querySelector(`svg[${i}]`)??void 0,this.svg!==t&&(this.svgComputedStyle=this.svg?window.getComputedStyle(this.svg):void 0),this.container=this.svg?.querySelector(`span[${n}]`)??void 0,this.observe()}disconnectedCallback(){this.svg=void 0,this.svgComputedStyle=void 0,this.wrapper=void 0,this.container=void 0,this.observe()}attributeChangedCallback(){this.observe()}flushSvgDisplay(){const{svg:t}=this;t&&(t.style.display="inline",requestAnimationFrame((()=>{t.style.display=""})))}observe(){this.containerObserver.disconnect(),this.wrapperObserver.disconnect(),this.wrapper&&this.wrapperObserver.observe(this.wrapper),this.container&&this.containerObserver.observe(this.container),this.svgComputedStyle&&this.observeSVGStyle(this.svgComputedStyle)}observeSVGStyle(t){const e=()=>{const i=(()=>{const e=t.getPropertyValue("--preserve-aspect-ratio");if(e)return e.trim();return`x${(({textAlign:t,direction:e})=>{if(t.endsWith("left"))return"Min";if(t.endsWith("right"))return"Max";if("start"===t||"end"===t){let i="rtl"===e;return"end"===t&&(i=!i),i?"Max":"Min"}return"Mid"})(t)}YMid meet`})();i!==this.svgPreserveAspectRatio&&(this.svgPreserveAspectRatio=i,this.updateSVGRect()),t===this.svgComputedStyle&&requestAnimationFrame(e)};e()}updateSVGRect(){let t=Math.ceil(this.containerSize?.width??0);const e=Math.ceil(this.containerSize?.height??0);void 0!==this.dataset.downscaleOnly&&(t=Math.max(t,this.wrapperSize?.width??0));const i=this.svg?.querySelector(":scope > foreignObject");if(i?.setAttribute("width",`${t}`),i?.setAttribute("height",`${e}`),this.svg&&(this.svg.setAttribute("viewBox",`0 0 ${t} ${e}`),this.svg.setAttribute("preserveAspectRatio",this.svgPreserveAspectRatio),this.svg.style.height=t<=0||e<=0?"0":""),this.container){const t=this.svgPreserveAspectRatio.toLowerCase();this.container.style.marginLeft=t.startsWith("xmid")||t.startsWith("xmax")?"auto":"0",this.container.style.marginRight=t.startsWith("xmi")?"auto":"0"}}}const r=(t,{attrs:e={},style:i})=>class extends t{constructor(...t){super(...t);for(const[t,i]of Object.entries(e))this.hasAttribute(t)||this.setAttribute(t,i);this._shadow()}static get observedAttributes(){return["data-auto-scaling"]}connectedCallback(){this._update()}attributeChangedCallback(){this._update()}_shadow(){if(!this.shadowRoot)try{this.attachShadow({mode:"open"})}catch(t){if(!(t instanceof Error&&"NotSupportedError"===t.name))throw t}return this.shadowRoot}_update(){const t=this._shadow();if(t){const e=i?`<style>:host { ${i} }</style>`:"";let n="<slot></slot>";const{autoScaling:s}=this.dataset;if(void 0!==s){n=`<marp-auto-scaling exportparts="svg:auto-scaling" ${"downscale-only"===s?"data-downscale-only":""}>${n}</marp-auto-scaling>`}t.innerHTML=e+n}}};let o;const a=Symbol();let l;const c="marpitSVGPolyfill:setZoomFactor,",d=Symbol(),h=Symbol();const g=()=>{const t="Apple Computer, Inc."===navigator.vendor,e=t?[u]:[],i={then:e=>(t?(async()=>{if(void 0===l){const t=document.createElement("canvas");t.width=10,t.height=10;const e=t.getContext("2d"),i=new Image(10,10),n=new Promise((t=>{i.addEventListener("load",(()=>t()))}));i.crossOrigin="anonymous",i.src="data:image/svg+xml;charset=utf8,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20width%3D%2210%22%20height%3D%2210%22%20viewBox%3D%220%200%201%201%22%3E%3CforeignObject%20width%3D%221%22%20height%3D%221%22%20requiredExtensions%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%3E%3Cdiv%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%20style%3D%22width%3A%201px%3B%20height%3A%201px%3B%20background%3A%20red%3B%20position%3A%20relative%22%3E%3C%2Fdiv%3E%3C%2FforeignObject%3E%3C%2Fsvg%3E",await n,e.drawImage(i,0,0),l=e.getImageData(5,5,1,1).data[3]<128}return l})().then((t=>{null==e||e(t?[u]:[])})):null==e||e([]),i)};return Object.assign(e,i)};let p,m;function u(t){const e="object"==typeof t&&t.target||document,i="object"==typeof t?t.zoom:t;window[h]||(Object.defineProperty(window,h,{configurable:!0,value:!0}),document.body.style.zoom=1.0001,document.body.offsetHeight,document.body.style.zoom=1,window.addEventListener("message",(({data:t,origin:e})=>{if(e===window.origin)try{if(t&&"string"==typeof t&&t.startsWith(c)){const[,e]=t.split(","),i=Number.parseFloat(e);Number.isNaN(i)||(m=i)}}catch(t){console.error(t)}})));let n=!1;Array.from(e.querySelectorAll("svg[data-marpit-svg]"),(t=>{var e,s,r,o;t.style.transform||(t.style.transform="translateZ(0)");const a=i||m||t.currentScale||1;p!==a&&(p=a,n=a);const l=t.getBoundingClientRect(),{length:c}=t.children;for(let i=0;i<c;i+=1){const n=t.children[i];if(n.getScreenCTM){const t=n.getScreenCTM();if(t){const i=null!==(s=null===(e=n.x)||void 0===e?void 0:e.baseVal.value)&&void 0!==s?s:0,c=null!==(o=null===(r=n.y)||void 0===r?void 0:r.baseVal.value)&&void 0!==o?o:0,d=n.children.length;for(let e=0;e<d;e+=1){const s=n.children[e];if("SECTION"===s.tagName){const{style:e}=s;e.transformOrigin||(e.transformOrigin=`${-i}px ${-c}px`),e.transform=`scale(${a}) matrix(${t.a}, ${t.b}, ${t.c}, ${t.d}, ${t.e-l.left}, ${t.f-l.top}) translateZ(0.0001px)`;break}}}}}})),!1!==n&&Array.from(e.querySelectorAll("iframe"),(({contentWindow:t})=>{null==t||t.postMessage(`${c}${n}`,"null"===window.origin?"*":window.origin)}))}function v({once:t=!1,target:e=document}={}){const i=function(t=document){if(t[d])return t[d];let e=!0;const i=()=>{e=!1,delete t[d]};Object.defineProperty(t,d,{configurable:!0,value:i});let n=[],s=!1;(async()=>{try{n=await g()}finally{s=!0}})();const r=()=>{for(const e of n)e({target:t});s&&0===n.length||e&&window.requestAnimationFrame(r)};return r(),i}(e);return t?(i(),()=>{}):i}p=1,m=void 0;const w=Symbol(),b=(e=document)=>{if("undefined"==typeof window)throw new Error("Marp Core's browser script is valid only in browser context.");if(((e=document)=>{const i=window[a];i||customElements.define("marp-auto-scaling",s);for(const n of Object.keys(t)){const s=`marp-${n}`,a=t[n].proto();(o??(o=!!document.createElement("div",{is:"marp-auto-scaling"}).outerHTML.startsWith("<div is"),o))&&a!==HTMLElement?i||customElements.define(s,r(a,{style:t[n].style}),{extends:n}):(i||customElements.define(s,r(HTMLElement,t[n])),e.querySelectorAll(`${n}[is="${s}"]`).forEach((t=>{t.outerHTML=t.outerHTML.replace(new RegExp(`^<${n}`,"i"),`<${s}`).replace(new RegExp(`</${n}>$`,"i"),`</${s}>`)})))}window[a]=!0})(e),e[w])return e[w];const i=v({target:e}),n=()=>{i(),delete e[w]},l=Object.assign(n,{cleanup:n,update:()=>b(e)});return Object.defineProperty(e,w,{configurable:!0,value:l}),l},y=document.currentScript;b(y?y.getRootNode():document)}();
</script></foreignObject></svg></div></body></html><div class="bespoke-marp-note" data-index="0" tabindex="0"><p>![RLQ h:50](https://i.imgur.com/3fIm24v.png)</p></div><div class="bespoke-marp-note" data-index="32" tabindex="0"><p>A phase III trial (ABC-02) randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter), each administered on days 1 and 8, every 3 weeks for eight cycles, or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks. The primary end point was overall survival.</p><p>The median overall survival was 11.7 months among the 204 patients in the cisplatin–gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; P&lt;0.001).</p><p>The median progression-free survival was 8.0 months in the cisplatin–gemcitabine group and 5.0 months in the gemcitabine-only group (P&lt;0.001). In addition, the rate of tumor control among patients in the cisplatin–gemcitabine group was significantly increased (81.4% vs. 71.8%, P=0.049).</p></div><div class="bespoke-marp-note" data-index="40" tabindex="0"><p>單純以中位數存活來看，只有改善約一個月左右的時間，效果似乎不是非常好，但是從存活曲線來看，可以發現兩年存活率 24.9% vs. 10.4%，相差超過兩倍，以白話來說，＂傳統化學治療兩年存活率只有一成，但是使用免疫治療有四分之一的機會活超過兩年＂，這些長期存活的個案，在未來追蹤更久的資料可以告訴我們這些病患是否能夠長期存活達到治癒的機會。</p></div><div class="bespoke-marp-note" data-index="52" tabindex="0"><p>The most common adverse reactions occurring in 20% or more of patients were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.</p></div><div class="bespoke-marp-note" data-index="70" tabindex="0"><p>![bg right:50% h:250px](https://i.imgur.com/ZxXHT4V.png)</p></div><script>/*!! License: https://unpkg.com/@marp-team/marp-cli@4.0.3/lib/bespoke.js.LICENSE.txt */
!function(){"use strict";function e(e){return e&&e.__esModule&&Object.prototype.hasOwnProperty.call(e,"default")?e.default:e}var t,n,r=(n||(n=1,t={from:function(e,t){var n,r=1===(e.parent||e).nodeType?e.parent||e:document.querySelector(e.parent||e),o=[].filter.call("string"==typeof e.slides?r.querySelectorAll(e.slides):e.slides||r.children,(function(e){return"SCRIPT"!==e.nodeName})),a={},i=function(e,t){return(t=t||{}).index=o.indexOf(e),t.slide=e,t},s=function(e,t){a[e]=(a[e]||[]).filter((function(e){return e!==t}))},c=function(e,t){return(a[e]||[]).reduce((function(e,n){return e&&!1!==n(t)}),!0)},l=function(e,t){o[e]&&(n&&c("deactivate",i(n,t)),n=o[e],c("activate",i(n,t)))},d=function(e,t){var r=o.indexOf(n)+e;c(e>0?"next":"prev",i(n,t))&&l(r,t)},u={off:s,on:function(e,t){return(a[e]||(a[e]=[])).push(t),s.bind(null,e,t)},fire:c,slide:function(e,t){if(!arguments.length)return o.indexOf(n);c("slide",i(o[e],t))&&l(e,t)},next:d.bind(null,1),prev:d.bind(null,-1),parent:r,slides:o,destroy:function(e){c("destroy",i(n,e)),a={}}};return(t||[]).forEach((function(e){e(u)})),n||l(0),u}}),t),o=e(r);const a=document.body,i=(...e)=>history.replaceState(...e),s="",c="presenter",l="next",d=["",c,l],u="bespoke-marp-",f=`data-${u}`,m=(e,{protocol:t,host:n,pathname:r,hash:o}=location)=>{const a=e.toString();return`${t}//${n}${r}${a?"?":""}${a}${o}`},g=()=>a.dataset.bespokeView,p=e=>new URLSearchParams(location.search).get(e),v=(e,t={})=>{const n={location,setter:i,...t},r=new URLSearchParams(n.location.search);for(const t of Object.keys(e)){const n=e[t];"string"==typeof n?r.set(t,n):r.delete(t)}try{n.setter({...window.history.state??{}},"",m(r,n.location))}catch(e){console.error(e)}},h=(()=>{const e="bespoke-marp";try{return localStorage.setItem(e,e),localStorage.removeItem(e),!0}catch{return!1}})(),y=e=>{try{return localStorage.getItem(e)}catch{return null}},b=(e,t)=>{try{return localStorage.setItem(e,t),!0}catch{return!1}},w=e=>{try{return localStorage.removeItem(e),!0}catch{return!1}},x=(e,t)=>{const n="aria-hidden";t?e.setAttribute(n,"true"):e.removeAttribute(n)},k=e=>{e.parent.classList.add(`${u}parent`),e.slides.forEach((e=>e.classList.add(`${u}slide`))),e.on("activate",(t=>{const n=`${u}active`,r=t.slide,o=r.classList,a=!o.contains(n);if(e.slides.forEach((e=>{e.classList.remove(n),x(e,!0)})),o.add(n),x(r,!1),a){const e=`${n}-ready`;o.add(e),document.body.clientHeight,o.remove(e)}}))},$=e=>{let t=0,n=0;Object.defineProperty(e,"fragments",{enumerable:!0,value:e.slides.map((e=>[null,...e.querySelectorAll("[data-marpit-fragment]")]))});const r=r=>void 0!==e.fragments[t][n+r],o=(r,o)=>{t=r,n=o,e.fragments.forEach(((e,t)=>{e.forEach(((e,n)=>{if(null==e)return;const a=t<r||t===r&&n<=o;e.setAttribute(`${f}fragment`,(a?"":"in")+"active");const i=`${f}current-fragment`;t===r&&n===o?e.setAttribute(i,"current"):e.removeAttribute(i)}))})),e.fragmentIndex=o;const a={slide:e.slides[r],index:r,fragments:e.fragments[r],fragmentIndex:o};e.fire("fragment",a)};e.on("next",(({fragment:a=!0})=>{if(a){if(r(1))return o(t,n+1),!1;const a=t+1;e.fragments[a]&&o(a,0)}else{const r=e.fragments[t].length;if(n+1<r)return o(t,r-1),!1;const a=e.fragments[t+1];a&&o(t+1,a.length-1)}})),e.on("prev",(({fragment:a=!0})=>{if(r(-1)&&a)return o(t,n-1),!1;const i=t-1;e.fragments[i]&&o(i,e.fragments[i].length-1)})),e.on("slide",(({index:t,fragment:n})=>{let r=0;if(void 0!==n){const o=e.fragments[t];if(o){const{length:e}=o;r=-1===n?e-1:Math.min(Math.max(n,0),e-1)}}o(t,r)})),o(0,0)},E=document,L=()=>!(!E.fullscreenEnabled&&!E.webkitFullscreenEnabled),S=()=>!(!E.fullscreenElement&&!E.webkitFullscreenElement),P=e=>{e.fullscreen=()=>{L()&&(async()=>{S()?(E.exitFullscreen||E.webkitExitFullscreen)?.call(E):((e=E.body)=>{(e.requestFullscreen||e.webkitRequestFullscreen)?.call(e)})()})()},document.addEventListener("keydown",(t=>{"f"!==t.key&&"F11"!==t.key||t.altKey||t.ctrlKey||t.metaKey||!L()||(e.fullscreen(),t.preventDefault())}))},_=`${u}inactive`,T=(e=2e3)=>({parent:t,fire:n})=>{const r=t.classList,o=e=>n(`marp-${e?"":"in"}active`);let a;const i=()=>{a&&clearTimeout(a),a=setTimeout((()=>{r.add(_),o()}),e),r.contains(_)&&(r.remove(_),o(!0))};for(const e of["mousedown","mousemove","touchend"])document.addEventListener(e,i);setTimeout(i,0)},I=["AUDIO","BUTTON","INPUT","SELECT","TEXTAREA","VIDEO"],M=e=>{e.parent.addEventListener("keydown",(e=>{if(!e.target)return;const t=e.target;(I.includes(t.nodeName)||"true"===t.contentEditable)&&e.stopPropagation()}))},O=e=>{window.addEventListener("load",(()=>{for(const t of e.slides){const e=t.querySelector("marp-auto-scaling, [data-auto-scaling], [data-marp-fitting]");t.setAttribute(`${f}load`,e?"":"hideable")}}))},A=({interval:e=250}={})=>t=>{document.addEventListener("keydown",(e=>{if(" "===e.key&&e.shiftKey)t.prev();else if("ArrowLeft"===e.key||"ArrowUp"===e.key||"PageUp"===e.key)t.prev({fragment:!e.shiftKey});else if(" "!==e.key||e.shiftKey)if("ArrowRight"===e.key||"ArrowDown"===e.key||"PageDown"===e.key)t.next({fragment:!e.shiftKey});else if("End"===e.key)t.slide(t.slides.length-1,{fragment:-1});else{if("Home"!==e.key)return;t.slide(0)}else t.next();e.preventDefault()}));let n,r,o=0;t.parent.addEventListener("wheel",(a=>{let i=!1;const s=(e,t)=>{e&&(i=i||((e,t)=>((e,t)=>{const n="X"===t?"Width":"Height";return e[`client${n}`]<e[`scroll${n}`]})(e,t)&&((e,t)=>{const{overflow:n}=e,r=e[`overflow${t}`];return"auto"===n||"scroll"===n||"auto"===r||"scroll"===r})(getComputedStyle(e),t))(e,t)),e?.parentElement&&s(e.parentElement,t)};if(0!==a.deltaX&&s(a.target,"X"),0!==a.deltaY&&s(a.target,"Y"),i)return;a.preventDefault();const c=Math.sqrt(a.deltaX**2+a.deltaY**2);if(void 0!==a.wheelDelta){if(void 0===a.webkitForce&&Math.abs(a.wheelDelta)<40)return;if(a.deltaMode===a.DOM_DELTA_PIXEL&&c<4)return}else if(a.deltaMode===a.DOM_DELTA_PIXEL&&c<12)return;r&&clearTimeout(r),r=setTimeout((()=>{n=0}),e);const l=Date.now()-o<e,d=c<=n;if(n=c,l||d)return;let u;(a.deltaX>0||a.deltaY>0)&&(u="next"),(a.deltaX<0||a.deltaY<0)&&(u="prev"),u&&(t[u](),o=Date.now())}))},C=(e=`.${u}osc`)=>{const t=document.querySelector(e);if(!t)return()=>{};const n=(e,n)=>{t.querySelectorAll(`[${f}osc=${JSON.stringify(e)}]`).forEach(n)};return L()||n("fullscreen",(e=>e.style.display="none")),h||n("presenter",(e=>{e.disabled=!0,e.title="Presenter view is disabled due to restricted localStorage."})),e=>{t.addEventListener("click",(t=>{if(t.target instanceof HTMLElement){const{bespokeMarpOsc:n}=t.target.dataset;n&&t.target.blur();const r={fragment:!t.shiftKey};"next"===n?e.next(r):"prev"===n?e.prev(r):"fullscreen"===n?e?.fullscreen():"presenter"===n&&e.openPresenterView()}})),e.parent.appendChild(t),e.on("activate",(({index:t})=>{n("page",(n=>n.textContent=`Page ${t+1} of ${e.slides.length}`))})),e.on("fragment",(({index:t,fragments:r,fragmentIndex:o})=>{n("prev",(e=>e.disabled=0===t&&0===o)),n("next",(n=>n.disabled=t===e.slides.length-1&&o===r.length-1))})),e.on("marp-active",(()=>x(t,!1))),e.on("marp-inactive",(()=>x(t,!0))),L()&&(e=>{for(const t of["","webkit"])E.addEventListener(t+"fullscreenchange",e)})((()=>n("fullscreen",(e=>e.classList.toggle("exit",L()&&S())))))}},D=e=>{window.addEventListener("message",(t=>{if(t.origin!==window.origin)return;const[n,r]=t.data.split(":");if("navigate"===n){const[t,n]=r.split(",");let o=Number.parseInt(t,10),a=Number.parseInt(n,10)+1;a>=e.fragments[o].length&&(o+=1,a=0),e.slide(o,{fragment:a})}}))};var N,B,q,K,j,F,V,U={exports:{}},X=(N||(N=1,U.exports=(B=["area","base","br","col","command","embed","hr","img","input","keygen","link","meta","param","source","track","wbr"],q=function(e){return String(e).replace(/[&<>"']/g,(function(e){return"&"+K[e]+";"}))},K={"&":"amp","<":"lt",">":"gt",'"':"quot","'":"apos"},j="dangerouslySetInnerHTML",F={className:"class",htmlFor:"for"},V={},function(e,t){var n=[],r="";t=t||{};for(var o=arguments.length;o-- >2;)n.push(arguments[o]);if("function"==typeof e)return t.children=n.reverse(),e(t);if(e){if(r+="<"+e,t)for(var a in t)!1!==t[a]&&null!=t[a]&&a!==j&&(r+=" "+(F[a]?F[a]:q(a))+'="'+q(t[a])+'"');r+=">"}if(-1===B.indexOf(e)){if(t[j])r+=t[j].__html;else for(;n.length;){var i=n.pop();if(i)if(i.pop)for(var s=i.length;s--;)n.push(i[s]);else r+=!0===V[i]?i:q(i)}r+=e?"</"+e+">":""}return V[r]=!0,r})),U.exports),H=e(X);const R=({children:e})=>H(null,null,...e),W=`${u}presenter-`,J={container:`${W}container`,dragbar:`${W}dragbar-container`,next:`${W}next`,nextContainer:`${W}next-container`,noteContainer:`${W}note-container`,noteWrapper:`${W}note-wrapper`,noteButtons:`${W}note-buttons`,infoContainer:`${W}info-container`,infoPage:`${W}info-page`,infoPageText:`${W}info-page-text`,infoPagePrev:`${W}info-page-prev`,infoPageNext:`${W}info-page-next`,noteButtonsBigger:`${W}note-bigger`,noteButtonsSmaller:`${W}note-smaller`,infoTime:`${W}info-time`,infoTimer:`${W}info-timer`},Y=e=>{const{title:t}=document;document.title="[Presenter view]"+(t?` - ${t}`:"");const n={},r=e=>(n[e]=n[e]||document.querySelector(`.${e}`),n[e]);document.body.appendChild((e=>{const t=document.createElement("div");return t.className=J.container,t.appendChild(e),t.insertAdjacentHTML("beforeend",H(R,null,H("div",{class:J.nextContainer},H("iframe",{class:J.next,src:"?view=next"})),H("div",{class:J.dragbar}),H("div",{class:J.noteContainer},H("div",{class:J.noteWrapper}),H("div",{class:J.noteButtons},H("button",{class:J.noteButtonsSmaller,tabindex:"-1",title:"Smaller notes font size"},"Smaller notes font size"),H("button",{class:J.noteButtonsBigger,tabindex:"-1",title:"Bigger notes font size"},"Bigger notes font size"))),H("div",{class:J.infoContainer},H("div",{class:J.infoPage},H("button",{class:J.infoPagePrev,tabindex:"-1",title:"Previous"},"Previous"),H("span",{class:J.infoPageText}),H("button",{class:J.infoPageNext,tabindex:"-1",title:"Next"},"Next")),H("time",{class:J.infoTime,title:"Current time"}),H("time",{class:J.infoTimer,title:"Timer"})))),t})(e.parent)),(e=>{let t=!1;r(J.dragbar).addEventListener("mousedown",(()=>{t=!0,r(J.dragbar).classList.add("active")})),window.addEventListener("mouseup",(()=>{t=!1,r(J.dragbar).classList.remove("active")})),window.addEventListener("mousemove",(e=>{if(!t)return;const n=e.clientX/document.documentElement.clientWidth*100;r(J.container).style.setProperty("--bespoke-marp-presenter-split-ratio",`${Math.max(0,Math.min(100,n))}%`)})),r(J.nextContainer).addEventListener("click",(()=>e.next()));const n=r(J.next),o=(a=n,(e,t)=>a.contentWindow?.postMessage(`navigate:${e},${t}`,"null"===window.origin?"*":window.origin));var a;n.addEventListener("load",(()=>{r(J.nextContainer).classList.add("active"),o(e.slide(),e.fragmentIndex),e.on("fragment",(({index:e,fragmentIndex:t})=>o(e,t)))}));const i=document.querySelectorAll(".bespoke-marp-note");i.forEach((e=>{e.addEventListener("keydown",(e=>e.stopPropagation())),r(J.noteWrapper).appendChild(e)})),e.on("activate",(()=>i.forEach((t=>t.classList.toggle("active",t.dataset.index==e.slide())))));let s=0;const c=e=>{s=Math.max(-5,s+e),r(J.noteContainer).style.setProperty("--bespoke-marp-note-font-scale",(1.2**s).toFixed(4))},l=()=>c(1),d=()=>c(-1),u=r(J.noteButtonsBigger),f=r(J.noteButtonsSmaller);u.addEventListener("click",(()=>{u.blur(),l()})),f.addEventListener("click",(()=>{f.blur(),d()})),document.addEventListener("keydown",(e=>{"+"===e.key&&l(),"-"===e.key&&d()}),!0),e.on("activate",(({index:t})=>{r(J.infoPageText).textContent=`${t+1} / ${e.slides.length}`}));const m=r(J.infoPagePrev),g=r(J.infoPageNext);m.addEventListener("click",(t=>{m.blur(),e.prev({fragment:!t.shiftKey})})),g.addEventListener("click",(t=>{g.blur(),e.next({fragment:!t.shiftKey})})),e.on("fragment",(({index:t,fragments:n,fragmentIndex:r})=>{m.disabled=0===t&&0===r,g.disabled=t===e.slides.length-1&&r===n.length-1}));let p=new Date;const v=()=>{const e=new Date,t=e=>`${Math.floor(e)}`.padStart(2,"0"),n=e.getTime()-p.getTime(),o=t(n/1e3%60),a=t(n/1e3/60%60),i=t(n/36e5%24);r(J.infoTime).textContent=e.toLocaleTimeString(),r(J.infoTimer).textContent=`${i}:${a}:${o}`};v(),setInterval(v,250),r(J.infoTimer).addEventListener("click",(()=>{p=new Date}))})(e)},z=e=>{if(!(e=>e.syncKey&&"string"==typeof e.syncKey)(e))throw new Error("The current instance of Bespoke.js is invalid for Marp bespoke presenter plugin.");Object.defineProperties(e,{openPresenterView:{enumerable:!0,value:G},presenterUrl:{enumerable:!0,get:Q}}),h&&document.addEventListener("keydown",(t=>{"p"!==t.key||t.altKey||t.ctrlKey||t.metaKey||(t.preventDefault(),e.openPresenterView())}))};function G(){const{max:e,floor:t}=Math,n=e(t(.85*window.innerWidth),640),r=e(t(.85*window.innerHeight),360);return window.open(this.presenterUrl,W+this.syncKey,`width=${n},height=${r},menubar=no,toolbar=no`)}function Q(){const e=new URLSearchParams(location.search);return e.set("view","presenter"),e.set("sync",this.syncKey),m(e)}const Z=e=>{const t=g();return t===l&&e.appendChild(document.createElement("span")),{[s]:z,[c]:Y,[l]:D}[t]},ee=e=>{e.on("activate",(t=>{document.querySelectorAll(".bespoke-progress-parent > .bespoke-progress-bar").forEach((n=>{n.style.flexBasis=100*t.index/(e.slides.length-1)+"%"}))}))},te=e=>{const t=Number.parseInt(e,10);return Number.isNaN(t)?null:t},ne=(e={})=>{const t={history:!0,...e};return e=>{let n=!0;const r=e=>{const t=n;try{return n=!0,e()}finally{n=t}},o=(t={fragment:!0})=>{let n=t.fragment?te(p("f")||""):null;((t,n)=>{const{min:r,max:o}=Math,{fragments:a,slides:i}=e,s=o(0,r(t,i.length-1)),c=o(0,r(n||0,a[s].length-1));s===e.slide()&&c===e.fragmentIndex||e.slide(s,{fragment:c})})((()=>{if(location.hash){const[t]=location.hash.slice(1).split(":~:");if(/^\d+$/.test(t))return(te(t)??1)-1;const r=document.getElementById(t)||document.querySelector(`a[name="${CSS.escape(t)}"]`);if(r){const{length:t}=e.slides;for(let o=0;o<t;o+=1)if(e.slides[o].contains(r)){const t=e.fragments?.[o],a=r.closest("[data-marpit-fragment]");if(t&&a){const e=t.indexOf(a);e>=0&&(n=e)}return o}}}return 0})(),n)};e.on("fragment",(({index:e,fragmentIndex:r})=>{n||v({f:0===r||r.toString()},{location:{...location,hash:`#${e+1}`},setter:(...e)=>t.history?history.pushState(...e):history.replaceState(...e)})})),setTimeout((()=>{o(),window.addEventListener("hashchange",(()=>r((()=>{o({fragment:!1}),v({f:void 0})})))),window.addEventListener("popstate",(()=>{n||r((()=>o()))})),n=!1}),0)}},re=(e={})=>{const t=e.key||window.history.state?.marpBespokeSyncKey||Math.random().toString(36).slice(2),n=`bespoke-marp-sync-${t}`;var r;r={marpBespokeSyncKey:t},v({},{setter:(e,...t)=>i({...e,...r},...t)});const o=()=>{const e=y(n);return e?JSON.parse(e):Object.create(null)},a=e=>{const t=o(),r={...t,...e(t)};return b(n,JSON.stringify(r)),r},s=()=>{window.removeEventListener("pageshow",s),a((e=>({reference:(e.reference||0)+1})))};return e=>{s(),Object.defineProperty(e,"syncKey",{value:t,enumerable:!0});let r=!0;setTimeout((()=>{e.on("fragment",(e=>{r&&a((()=>({index:e.index,fragmentIndex:e.fragmentIndex})))}))}),0),window.addEventListener("storage",(t=>{if(t.key===n&&t.oldValue&&t.newValue){const n=JSON.parse(t.oldValue),o=JSON.parse(t.newValue);if(n.index!==o.index||n.fragmentIndex!==o.fragmentIndex)try{r=!1,e.slide(o.index,{fragment:o.fragmentIndex,forSync:!0})}finally{r=!0}}}));const i=()=>{const{reference:e}=o();void 0===e||e<=1?w(n):a((()=>({reference:e-1})))};window.addEventListener("pagehide",(e=>{e.persisted&&window.addEventListener("pageshow",s),i()})),e.on("destroy",i)}},{PI:oe,abs:ae,sqrt:ie,atan2:se}=Math,ce={passive:!0},le=({slope:e=-.7,swipeThreshold:t=30}={})=>n=>{let r;const o=n.parent,a=e=>{const t=o.getBoundingClientRect();return{x:e.pageX-(t.left+t.right)/2,y:e.pageY-(t.top+t.bottom)/2}};o.addEventListener("touchstart",(({touches:e})=>{r=1===e.length?a(e[0]):void 0}),ce),o.addEventListener("touchmove",(e=>{if(r)if(1===e.touches.length){e.preventDefault();const t=a(e.touches[0]),n=t.x-r.x,o=t.y-r.y;r.delta=ie(ae(n)**2+ae(o)**2),r.radian=se(n,o)}else r=void 0})),o.addEventListener("touchend",(o=>{if(r){if(r.delta&&r.delta>=t&&r.radian){const t=(r.radian-e+oe)%(2*oe)-oe;n[t<0?"next":"prev"](),o.stopPropagation()}r=void 0}}),ce)},de=new Map;de.clear(),de.set("none",{backward:{both:void 0,incoming:void 0,outgoing:void 0},forward:{both:void 0,incoming:void 0,outgoing:void 0}});const ue={both:"",outgoing:"outgoing-",incoming:"incoming-"},fe={forward:"",backward:"-backward"},me=e=>`--marp-bespoke-transition-animation-${e}`,ge=e=>`--marp-transition-${e}`,pe=me("name"),ve=me("duration"),he=e=>new Promise((t=>{const n={},r=document.createElement("div"),o=e=>{r.remove(),t(e)};r.addEventListener("animationstart",(()=>o(n))),Object.assign(r.style,{animationName:e,animationDuration:"1s",animationFillMode:"both",animationPlayState:"paused",position:"absolute",pointerEvents:"none"}),document.body.appendChild(r);const a=getComputedStyle(r).getPropertyValue(ge("duration"));a&&(n.defaultDuration=a),((e,t)=>{requestAnimationFrame((()=>{e.style.animationPlayState="running",requestAnimationFrame((()=>t(void 0)))}))})(r,o)})),ye=async e=>de.has(e)?de.get(e):(e=>{const t={},n=[];for(const[r,o]of Object.entries(ue))for(const[a,i]of Object.entries(fe)){const s=`marp-${o}transition${i}-${e}`;n.push(he(s).then((e=>{t[a]=t[a]||{},t[a][r]=e?{...e,name:s}:void 0})))}return Promise.all(n).then((()=>t))})(e).then((t=>(de.set(e,t),t))),be=e=>Object.values(e).flatMap(Object.values).every((e=>!e)),we=(e,{type:t,backward:n})=>{const r=e[n?"backward":"forward"],o=(()=>{const e=r[t],n=e=>({[pe]:e.name});if(e)return n(e);if(r.both){const e=n(r.both);return"incoming"===t&&(e[me("direction")]="reverse"),e}})();return!o&&n?we(e,{type:t,backward:!1}):o||{[pe]:"__bespoke_marp_transition_no_animation__"}},xe=e=>{if(e)try{const t=JSON.parse(e);if((e=>{if("object"!=typeof e)return!1;const t=e;return"string"==typeof t.name&&(void 0===t.duration||"string"==typeof t.duration)})(t))return t}catch{}},ke="_tSId",$e="_tA",Ee="bespoke-marp-transition-warming-up",Le=window.matchMedia("(prefers-reduced-motion: reduce)"),Se="__bespoke_marp_transition_reduced_outgoing__",Pe="__bespoke_marp_transition_reduced_incoming__",_e={forward:{both:void 0,incoming:{name:Pe},outgoing:{name:Se}},backward:{both:void 0,incoming:{name:Pe},outgoing:{name:Se}}},Te=e=>{if(!document.startViewTransition)return;const t=t=>(void 0!==t&&(e._tD=t),e._tD);let n;t(!1),((...e)=>{const t=[...new Set(e).values()];return Promise.all(t.map((e=>ye(e)))).then()})(...Array.from(document.querySelectorAll("section[data-transition], section[data-transition-back]")).flatMap((e=>[e.dataset.transition,e.dataset.transitionBack].flatMap((e=>{const t=xe(e);return[t?.name,t?.builtinFallback?`__builtin__${t.name}`:void 0]})).filter((e=>!!e))))).then((()=>{document.querySelectorAll("style").forEach((e=>{e.innerHTML=e.innerHTML.replace(/--marp-transition-duration:[^;}]*[;}]/g,(e=>e.slice(0,-1)+"!important"+e.slice(-1)))}))}));const r=(n,{back:r,cond:o})=>a=>{const i=t();if(i)return!!a[$e]||!("object"!=typeof i||(i.skipTransition(),!a.forSync));if(!o(a))return!0;const s=e.slides[e.slide()],c=()=>a.back??r,l="data-transition"+(c()?"-back":""),d=s.querySelector(`section[${l}]`);if(!d)return!0;const u=xe(d.getAttribute(l)??void 0);return!u||((async(e,{builtinFallback:t=!0}={})=>{let n=await ye(e);if(be(n)){if(!t)return;return n=await ye(`__builtin__${e}`),be(n)?void 0:n}return n})(u.name,{builtinFallback:u.builtinFallback}).then((e=>{if(!e){t(!0);try{n(a)}finally{t(!1)}return}let r=e;Le.matches&&(console.warn("Use a constant animation to transition because preferring reduced motion by viewer has detected."),r=_e);const o=document.getElementById(ke);o&&o.remove();const i=document.createElement("style");i.id=ke,document.head.appendChild(i),((e,t)=>{const n=[`:root{${ge("direction")}:${t.backward?-1:1};}`,":root:has(.bespoke-marp-inactive){cursor:none;}"],r=t=>{const n=e[t].both?.defaultDuration||e[t].outgoing?.defaultDuration||e[t].incoming?.defaultDuration;return"forward"===t?n:n||r("forward")},o=t.duration||r(t.backward?"backward":"forward");void 0!==o&&n.push(`::view-transition-group(*){${ve}:${o};}`);const a=e=>Object.entries(e).map((([e,t])=>`${e}:${t};`)).join("");return n.push(`::view-transition-old(root){${a(we(e,{...t,type:"outgoing"}))}}`,`::view-transition-new(root){${a(we(e,{...t,type:"incoming"}))}}`),n})(r,{backward:c(),duration:u.duration}).forEach((e=>i.sheet?.insertRule(e)));const s=document.documentElement.classList;s.add(Ee);let l=!1;const d=()=>{l||(n(a),l=!0,s.remove(Ee))},f=()=>{t(!1),i.remove(),s.remove(Ee)};try{t(!0);const e=document.startViewTransition(d);t(e),e.finished.finally(f)}catch(e){console.error(e),d(),f()}})),!1)};e.on("prev",r((t=>e.prev({...t,[$e]:!0})),{back:!0,cond:e=>e.index>0&&!((e.fragment??1)&&n.fragmentIndex>0)})),e.on("next",r((t=>e.next({...t,[$e]:!0})),{cond:t=>t.index+1<e.slides.length&&!(n.fragmentIndex+1<n.fragments.length)})),setTimeout((()=>{e.on("slide",r((t=>e.slide(t.index,{...t,[$e]:!0})),{cond:t=>{const n=e.slide();return t.index!==n&&(t.back=t.index<n,!0)}}))}),0),e.on("fragment",(e=>{n=e}))};let Ie;const Me=()=>(void 0===Ie&&(Ie="wakeLock"in navigator&&navigator.wakeLock),Ie),Oe=async()=>{const e=Me();if(e)try{return await e.request("screen")}catch(e){console.warn(e)}return null},Ae=async()=>{if(!Me())return;let e;const t=()=>{e&&"visible"===document.visibilityState&&Oe()};for(const e of["visibilitychange","fullscreenchange"])document.addEventListener(e,t);return e=await Oe(),e};((e=document.getElementById(":$p"))=>{(()=>{const e=p("view");a.dataset.bespokeView=e===l||e===c?e:""})();const t=(e=>{const t=p(e);return v({[e]:void 0}),t})("sync")||void 0;o.from(e,((...e)=>{const t=d.findIndex((e=>g()===e));return e.map((([e,n])=>e[t]&&n)).filter((e=>e))})([[1,1,0],re({key:t})],[[1,1,1],Z(e)],[[1,1,0],M],[[1,1,1],k],[[1,0,0],T()],[[1,1,1],O],[[1,1,1],ne({history:!1})],[[1,1,0],A()],[[1,1,0],P],[[1,0,0],ee],[[1,1,0],le()],[[1,0,0],C()],[[1,0,0],Te],[[1,1,1],$],[[1,1,0],Ae]))})()}();</script></body></html>